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ABSTRACT 
Alzheimer disease (AD) is a neurodegenerative disorder characterized by progressive 
dementia with devastating effects for the patients and their families. The treatments available 
are purely symptomatic and there is need for treatment strategies aiming at the 
etiopathogenesis of AD. The effects of systemic inflammation on the development and/or 
progress of AD are not clarified. Present knowledge points towards both beneficial and 
detrimental effects of inflammation on AD, depending on both its timing and its nature. 
Allergy is associated with chronic systemic inflammatory changes, and its effects on the brain 
are largely unknown. Epidemiological studies have shown that allergic diseases were 
associated with increased risk for AD. The aim of this thesis was to investigate the effects of 
allergy on the normal brain and in association with AD-like pathology. 
In Paper I, we aimed to study whether chronic airway allergy affects the AD-related proteins 
amyloid precursor protein (APP) and hyperphosphorylated tau (p-tau), and the inflammatory 
status in the brain of naïve mice. We found that allergy increased p-tau levels in the brain, 
whereas levels of APP were not modified. Furthermore, the levels of immunoglobulin (Ig) G 
and E were significantly increased in the brain of allergic mice. The increase was not only 
confined to blood vessels but broadly in the brain parenchyma. We then aimed to study in 
Paper II the changes in gene expression induced by chronic airway allergy in the brain using 
microarray technology. Allergy induced changes in several inflammation-related signalling 
pathways. We found that the levels of insulin-degrading enzyme (IDE) and phosphorylated 
insulin receptor (p-IR) were decreased in the brain in response to allergy. In Paper III, we 
investigated the effects of chronic airway allergy on the brain in the 3xTgAD (Tg) mouse 
model for AD, and their background strain (Bg). The levels of IgG and IgE were also 
increased in the brain of Tg mice in response to allergy. Allergy increased the levels of C1q 
component C and interleukin-1β, decreased p-IR, and impaired the burrowing activity in Bg 
animals. The Tg mice showed increased levels of brain-derived neurotrophic factor and 
decay-accelerating factor (complement inhibitor), and decreased levels of phosphorylated 
p38. In paper IV, we analysed the levels of Igs and cytokines in cerebrospinal fluid (CSF) 
and serum obtained from patients with subjective cognitive impairment (SCI), mild cognitive 
impairment (MCI) and AD, with or without allergy. The relation of allergy to CSF 
biomarkers (p-tau, total (t)-tau, and β-amyloid (Aβ)) and mini-mental statement examination 
(MMSE) was investigated. We found that the CSF levels of IgG1 ratio, IgA and t-tau were 
lower in AD cases with allergy compared to those without allergy. The serum interferon γ 
levels were lower while MMSE scores were higher in MCI cases with allergy.  
In conclusion, our studies suggest that allergy may have negative effects on the normal brain 
but seemingly beneficial effects in the presence of AD-like pathology. It is possible that 
stimulation of immune responses induced by allergy may lead to beneficial effects on AD. So 
far, little is known regarding the association between AD and allergies and further studies are 
needed to clarify the impact of allergy on AD pathogenesis and progression.            
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PREWORDS 
Initial definition of inflammation dates back to the Roman Cornelius Celsus in the 1st century 
AD, who coined the first four cardinal signs of inflammation: Rubor et tumor cum calore et 
dolore (redness and swelling with heat and pain) (Scott et al., 2004). Two centuries later 
Galen promoted a humoral view, which persisted until the 19th century when the idea came 
that inflammation, especially pus cells, is a beneficial response to an injury. Although Celsus 
inflammation indicates an adequate acute inflammatory response following a traumatic 
injury, it falls short in describing the underlying cellular and molecular processes of the 
cardinal signs which may occur to induce inflammation at a sub-clinical level, but not be 
manifested as redness, swelling, heat or pain (Scott et al., 2004). This limitation was not 
overlooked by Rudolph Virchow – one of the greatest 19th century pioneers – who found that 
symptoms occurring due to increased blood flow (rubor and congestio) were absent in non-
vascularized tissues such as cornea or connective tissue. In contrast to Galen, Virchow’s 
inflammation was pathological and consisted of “inflammatory processes” rather than a 
single uniform process. He added an additional sign – functio laesa (loss of function), 
underlining the restriction in the function of inflamed tissue (Heidland et al., 2006). Virchow 
had observed an increased number of cells in inflammatory areas and believed that 
connective tissue was the breeding place for their formation. While Recklinghausen and 
Cohnheim disproved this concept by demonstrating the migration of inflammatory (pus) cells 
from their place of origin and the transmigration of leukocytes from the blood vessels into the 
local inflammatory area (diapedes) (Heidland et al., 2009), their contemporary Metchnikoff 
discovered a very important asset of inflammation – the phagocytosis (Gordon, 2008). The 
advances in microscopy during the 19th century encouraged cell-based understanding of 
inflammation, and the discovery in the 20th century of the molecular mediators of 
inflammation, namely histamine, kinins, anaphylatoxins, added another layer to the 
understanding of inflammation. Thus, a new definition of inflammation taking into account 
both the cellular and molecular events was proposed by Rocha e Silva as follows: “multi-
mediated phenomenon, of a pattern type in which all mediators would come and go at the 
appropriate moment… increasing vascular permeability, attracting leukocytes, producing 
pain, local edema and necrosis” (Rocha e Silva, 1978). It is obvious that Rocha e Silva’s 
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definition adds a biochemical perspective to the four cardinal signs but Celsus inflammation 
survives in the background and is still relevant.    
In last decades, inflammation has become one of the hottest topics in the medical research. 
The discovery of cellular and molecular mediators involved in inflammatory processes have 
changed the understanding of inflammation and therefore very divergent diseases – such as 
Alzheimer disease and asthma – have inflammation as a common denominator. 
 
1 INTRODUCTION 
1.1 Alzheimer disease  
1.1.1 Overview   
Alzheimer disease (AD) is a neurodegenerative disorder, which begins with a subtle 
impairment in memory formation but gradually affects other cognitive domains such as 
language, orientation, behaviour and executive functions such as planning, problem solving 
and judgment. The patients’ ability to function in daily life declines as the disease progresses 
and the patients become eventually completely dependent. AD is the most common type of 
dementia accounting for 50 - 70 % of dementia cases. The prevalence of dementia increases 
with age and the number of people with the age of 60 years or above is estimated to increase 
to 1.25 billion by 2050.  Today, more than 35 million people live with dementia in the world 
and the number is expected to double every 20 years, reaching more than 100 million by 
2050 (Prince et al., 2013). The estimated cost for dementia was approximately 604 billion 
USD in 2010, which corresponds to 1% of world’s gross domestic product (Wimo et al., 
2013). Thus the increasing dementia cases pose an enormous socioeconomic burden on the 
society and psychological burden on the family members and caregivers, not to mention the 
suffering of the patients. 
The first description of AD dates back to 1906 when the German physician Alois Alzheimer 
characterized the main pathological features of AD, amyloid plaque and neurofibrillary 
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current diagnostic criteria for AD (McKhann et al., 2011) and pointed out glial changes 
(Alzheimer et al., 1995) that were not considered as signs of inflammation until in eighties. 
Extensive research since last three decades has imparted the field with better understanding 
of the underlying disease mechanisms. The discovery of causative genetic mutations leading 
to familial AD (FAD) has played an important role in subsequent modeling of the disease 
both in vitro and in vivo for studying pathological processes associated with AD. Advances in 
the field of genetics have identified several risk genes among which Apolipoprotein E 
(APOE) 4 has shown the strongest link to AD (Corder et al., 1993). Epidemiological studies 
have highlighted the importance of environmental and lifestyle factors for the risk of 
developing AD. Imaging techniques, by investigating pathological processes in living 
patients, have shed light on the time course of pathological changes beginning already at pre-
symptomatic stages. Therefore, detecting early pathological changes before the development 
of symptoms such as memory loss was incorporated into the new diagnostic research 
guidelines termed as prodromal AD stage. In this front, identification of AD biomarkers, 
especially in body fluids such as cerebrospinal fluid (CSF) (Brinkmalm et al., 2014) and 
blood (Veitinger et al., 2014) are under investigation. The current criteria for diagnosing AD 
are based on clinical symptoms in combination with, if available, the cerebrospinal fluid 
(CSF) levels of AD biomarkers, amyloid β (Aβ), phosphorylated tau (p-tau), and total tau (t-
tau), and imaging techniques to investigate Aβ burden, brain glucose metabolism and brain 
volume (Alzheimer's, 2013).  
The available pharmacological treatments for AD improve the symptoms temporarily.    
Disease-modifying treatment strategies that were supposed to delay or halt the progression of 
AD have failed, despite numerous approaches, possibly because the beneficial therapeutic 
effect in already established AD with massive neuronal death is difficult to achieve. 
Furthermore, the potential beneficial effect of a therapy, if any, may have been obscured due 
to the disease heterogeneity in AD patients. Thus, combination of biomarkers, genetic 
information such as polymorphisms, epidemiological data such as risk factors and imaging 
techniques with cognitive assessment of AD patients, allow for better stratification of AD 
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patients, both at pre- and post-symptomatic stages, and will hopefully result in better 
outcomes in clinical trials.   
 
1.1.2 Risk and protective factors 
Risk factors for AD play an important role in the pathogenesis of the disease (Reitz et al., 
2011). In addition to aging, which is the most important risk factor, several gene variants that 
increase the risk for AD including, complement receptor type I (CR1), sortilin-related 
receptor 1, clusterin have been identified (Reitz et al., 2011). The most common risk gene 
associated with AD is apoE, a lipid-binding protein involved in cholesterol transport, which 
is present in three allelic variants: apoE2, apoE3 and apoE4. The heritage of a single apoE4 
allele increases the risk for AD 2-fold, and double copies of this gene are associated with a 7-
fold increase in the risk for AD (Raber et al., 2004).  
The heritability of late-onset AD is between 58 - 79 % (Humphries & Kohli, 2014) meaning 
that the remaining risk can be attributed to environmental risk factors. Cardiovascular and 
metabolic dysfunction such as hypercholesterolemia, hypertension, obesity and diabetes type 
2 (DT2) are associated with increased risk for developing AD (Meng et al., 2014). Other 
factors including smoking, depression, psychological stress, and traumatic brain injuries have 
been linked with increased risk for developing AD (Reitz et al., 2011).  Infections caused by 
viruses, especially herpes simplex virus type 1, and bacterial infections such as by 
Chlamydophila pneumoniae, the gram-negative bacteria spirochetes (Maheshwari & Eslick, 
2014), and helicobacter pylori (Adriani et al., 2014), have also been associated with 
increased risk for AD.  
Although the disease-modifying pharmacological treatment for AD have yet not been 
successful, preventive strategies have been proposed dependent on factors that influence life-
style. Diet rich in anti-oxidants and polyunsaturated fatty acids, physica and intellectual 
activity were associated with improved cognitive performance and decreased risk for 
developing AD (Reitz et al., 2011). In addition, genetic factors may also protect against AD. 
For example, a mutation in the amyloid precursor protein (APP) (A673T) gene in the 
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Islandic population above the age of 85, was associated with improved cognition and reduced 
risk for AD (Jonsson et al., 2012). The apoE2 gene protects against AD (Corder et al., 1994) 
probably by being associated with reduced hippocampal atrophy as observed in humans 
(Chiang et al., 2010), and increased Aβ clearance in AD mouse models (Hudry et al., 2013).   
 
1.1.3 Pathogenesis  
Amyloid plaques in AD brain are mainly composed of aggregated Aβ peptides that are 
derived from a sequential cleavage of APP by the β- and γ-secretase in the so-called 
amyloidogenic pathway. The non-amyloidogenic cleavage of APP by α-secretase instead of 
β-secretase, leads to formation of p3 fragments. In contrast to p3 fragments, Aβ peptides 
have the propensity to form aggregates and give rise to a wide range of higher molecular 
species ranging from small oligomers to protofibrils that later develop into amyloid plaques 
(Goto et al., 2008). Aβ is removed enzymatically from the brain, for example by insulin 
degrading enzyme (IDE) and neprilysin, as well as non-enzymatically by other clearance 
mechanisms such as phagocytosis, autophagy, drainage along perivascular basement 
membrane, and transport across blood brain barrier (BBB) through several mechanisms 
(Miners et al., 2011). The amyloid burden in the AD brain seems to be determined by the 
balance between the production and removal of Aβ (Hyman et al., 1993).  
NFTs are composed of hyperphosphorylated tau protein. Amyloid plaques and NFTs develop 
in distinct manner spatially and temporally, and are classified in stages A-C and stages I-VI 
respectively (Braak et al., 1993). Initially, amyloid deposits occur in neocortical regions 
(stage A), spread into isocortical regions including hippocampus and entorhinal cortex in 
some cases (stage B), and eventually spread into all isocortical areas including sensory and 
motor cortex and subcortical areas. Neurofibrillary changes begin in the transentorhinal 
regions (stage I-II), spread to hippocampus (stage III-VI), and finally reach isocortical 
regions (stage V-VI) (Braak & Braak, 1997; Thal et al., 2002).  
Mutations in APP (Goate et al., 1991), presenilin (PS) 1 and 2 (Rogaev et al., 1995; 
Sherrington et al., 1995) account for approximately 5% of AD cases implying that the 
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majority of AD cases are sporadic, with unknown cause. The fact that FAD mutations 
influence the production and processing of Aβ and leads to early onset AD supported the 
amyloid cascade hypothesis (Hardy & Higgins, 1992), which proposes that accumulation of 
Aβ is the initial cause for the downstream pathological events including NFT formation, 
neuronal loss, and subsequent dementia.  
Amyloid cascade hypothesis has been questioned due to gaps in providing a complete 
description of AD pathogenesis. Recent studies showed that, regardless of the presence or 
absence of Aβ, cognitively normal elderly with markers for neuronal injuries did not differ in 
glucose hypometabolism, hippocampal atrophy, and in conversion rates to AD. This is an 
argument against the role of Aβ as an initiator of downstream pathological events in AD 
(Chetelat, 2013; Knopman et al., 2013). Furthermore, the extent of NFTs and neuronal loss 
correlate better with the severity of dementia than the plaque load in the brain 
(Giannakopoulos et al., 2009). The absence of NTFs in mouse models for AD despite loads 
of Aβ in the brain (see Section 1.3.1) and the failure of clinical trials with Aβ-lowering 
interventions suggest that amyloid-independent pathological pathways may also occur in AD 
(Armstrong, 2014).  
Dysregulation of other cellular processes such as mitochondrial dysfunction (Lin & Beal, 
2006), increased oxidative stress, deficits in glucose metabolism, disturbance in clearance 
mechanisms i.e. autophagy and ubiquitin systems (Butterfield et al., 2014), and dysregulated 
inflammatory processes (Morales et al., 2014) have been implicated in the pathogenesis of 
AD. Thus sporadic AD is a multifactorial disease, which may originate from distinct 
underlying pathologies involving amyloid-dependent and -independent processes in a 
complex interplay between genetic and environmental factors. 
 
1.1.4 Inflammation in the brain in Alzheimer disease 
Evidence for the presence of inflammation in post mortem brain from AD patients was 
described for the first time in early eighties, when amyloid plaques were shown to be 
associated with immunoglobulins (Igs), complement components (C) 1q, C3 and C4 
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(Eikelenboom & Stam, 1982). Subsequent studies showed increased microglial activation, 
especially adjacent to the amyloid plaques (McGeer et al., 1987; McGeer et al., 1988), and 
increased production of the pro-inflammatory cytokines interleukin (IL)-1 and IL-6 (Griffin 
et al., 1989). Thus, the activity of multiple immune pathways including cytokines, 
complement system, membrane attack complex (MAC), chemokines, and acute phase 
proteins are increased in the AD brain (for extensive review see (Akiyama et al., 2000)). In 
vitro studies showed that Aβ per se contributed to inflammation by binding to receptors for 
advanced glycation end-product (Yan et al., 1996), scavenger receptors (El Khoury et al., 
1996; Paresce et al., 1996), toll-like receptors (TLRs) (Walter et al., 2007; Reed-Geaghan et 
al., 2009), to activate microglia and astrocytes. Activated glial cells produce a wide range of 
inflammatory mediators including complement factors, cytokines, reactive oxygen species 
(ROS), secreted proteases, excitatory amino acids, and nitric oxide (NO) (Akiyama et al., 
2000; Lyman et al., 2014) that can cause mitochondrial dysfunction (Wilkins et al., 2014), 
synaptic dysfunction, inhibition of neurogenesis, and neuronal death (Lyman et al., 2014). In 
addition, Aβ was shown to activate the classical (C1q) and alternative (C3) complement 
pathways (Tuppo & Arias, 2005), and to enhance the production of tumour necrosis factor α 
(TNFα), IL-1β and IL-6 (Del Bo et al., 1995; Pan et al., 2011). Stimulation with pro-
inflammatory cytokines, TNFα, interferon γ (IFNγ), IL-1β and IL-6, in turn increased the 
levels of Aβ by enhancing βAPP processing (Dash & Moore, 1995; Blasko et al., 2000; 
Yamamoto et al., 2007) to favour the amyloidogenic pathway or by enhancing the expression 
of APP (Ringheim et al., 1998), thus resulting in a self-perpetuating vicious circle (Del Bo et 
al., 1995).  
Activated microglia surrounding the amyloid plaques are found in the neocortex of patients 
with low Braak stages of AD-pathology, preceding the later stages that are characterized by 
neurofibrillary changes (Arends et al., 2000; Vehmas et al., 2003; Hoozemans et al., 2006). 
Studies in transgenic animal models of AD, by confirming the inflammatory aspects found in 
AD patients (Apelt & Schliebs, 2001; Abbas et al., 2002; Patel et al., 2005), not only 
supported the role of inflammatory processes in AD pathogenesis, but also highlighted 
inflammation as an early event in AD. For instance the increase in inflammatory response in 
3xTgAD mice (Janelsins et al., 2005) and Tg2576 mice (Tehranian et al., 2001) precedes 
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amyloid pathology. Studies in humans have shown that mild cognitive impairment (MCI) 
(see section 3.1.3) patients had increased levels of inflammatory markers in the CSF as 
compared to control subjects (Brosseron et al., 2014), with parallel increase in microglial 
(Okello et al., 2009; Fan et al., 2014) and astrocyte (Carter et al., 2012) activation in the brain 
as revealed by in vivo imaging studies, thus supporting the idea that inflammation is an early 
phenomenon in the course of AD. Interestingly, increased microglial activation was 
correlated with glucose hypometabolism in both AD and MCI patients (Fan et al., 2014), 
suggesting that microglial activation may be linked to synaptic dysfunction in these patients. 
In addition, these studies provide evidence that findings from in vivo studies in humans are in 
agreement with the findings obtained in mouse models for AD, which increase the reliability 
of models for translational purposes.  
There is evidence that infiltration of peripheral immune cells belonging to the innate immune 
arm, such as neutrophils (Baik et al., 2014), monocyte/macrophages and acquired immune 
arm, such as T-cells, occurs in the AD brain (Togo et al., 2002). The role of different T 
helper (Th) cell subsets has been well characterized in multiple sclerosis, but emerging data 
suggest a role for Th-17, Th-9 and Th-1 cells in the development of chronic inflammation in 
AD (Saresella et al., 2011; Gonzalez & Pacheco, 2014) although the knowledge in this field 
is limited. 
 
1.1.5 Systemic inflammation in Alzheimer disease 
Beyond the presence of inflammatory mediators in the brain of AD patients, several lines of 
evidence support the role of inflammation in AD pathogenesis. Genome-wide association 
studies revealed that polymorphisms in several genes encoding inflammatory proteins were 
associated with a risk for AD. Of particular interest are the genetic variants that influence the 
innate immunity such as triggering receptor expressed on myeloid 2 (TREM2), adenosine 
triphosphate - binding cassette subtype family A member 7 (ABCA7), and CR1 (Wilkins et 
al., 2014). TREM2 has been shown to suppress cytokine activation and to polarize microglia 
towards a phagocytic phenotype (Humphries & Kohli, 2014; Wilkins et al., 2014), ABCA7 
plays role in lipid transport across the membrane and regulates phagocytosis by macrophages 
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(Hollingworth et al., 2011), whereas CR1 activates complement pathway and phagocytosis 
(Wilkins et al., 2014). Interestingly, all these genes affect phagocytosis or the clearance 
mechanisms of the cell.   
Epidemiological studies in the middle of the 1990s revealed that chronic usage of non-
steroidal anti-inflammatory drugs (NSAIDs) reduced the risk of developing AD (McGeer et 
al., 1996), suggesting that systemic inflammation may play a role in AD. Furthermore, 
several risk factors for AD, including aging, obesity, diabetes, hypertension, and smoking 
(Reitz et al., 2010), are associated with increased systemic inflammation (Yaffe et al., 2004).  
Evidence for low-grade systemic inflammation has been found in the plasma and CSF of AD 
patients, with a shifted balance towards a pro-inflammatory profile (Ahluwalia & Vellas, 
2003). According to a meta-analysis, increased levels of IL-1β, IL-6, IL-12, IL-18, TNFα, 
and transforming growth factor (TGF) β were found in the plasma of AD patients, whereas 
only increased TGFβ was found in the CSF (Swardfager et al., 2010). Early studies focused 
on investigating the relationship between peripheral inflammatory markers and cognitive 
decline in old adults to assess predictive capacity of inflammatory markers for future 
dementia (Bettcher & Kramer, 2014). Some studies found that elevated levels of acute phase 
proteins such as C-reactive protein (CRP), α-1-antichymotrypsin, and cytokines including IL-
6 and TNFα, were associated with increased risk for AD in elderly subjects (Engelhart et al., 
2004; Dik et al., 2005; Dziedzic, 2006). Other studies found no association between baseline 
inflammation and future risk for AD or other dementia (for review see (Bettcher & Kramer, 
2014)), or even inverse correlation, especially in older ages when increased baseline levels of 
CRP were negatively associated with cognitive decline in the oldest old (median age 77 
years) (Lima et al., 2014).  Similar findings have been reported for cardiovascular factors that 
confer risk at midlife but show an inverse association with cognitive decline in later ages (van 
den Berg et al., 2007). It is possible that the early and late stages on the continuum towards 
AD have different underlying mechanisms.   
High plasma and CSF levels of soluble TNF-receptor I (TNFRI) in MCI were related to 
increased risk of conversion to AD (Buchhave et al., 2010; Diniz et al., 2010). With regard to 
association between the levels of inflammatory markers and cognitive decline, AD patients 
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with high serum TNFα levels at baseline had increased cognitive decline compared to those 
with low serum levels of TNFα (Holmes et al., 2009). In addition, acute inflammatory events 
such as infection and trauma (Holmes et al., 2009) or delirium (Cunningham, 2011) were 
associated with further increase in cognitive decline. Leung et al. found an association 
between the cytokine levels in plasma and disease severity when AD patients were divided 
based on their cognitive decline into slow, intermediate and fast decliners (Leung et al., 
2013).  Interestingly, the levels of anti-inflammatory cytokines IL-4 and IL-10 were increased 
in the fast decliners, whereas the pro-inflammatory cytokines IL-2 and IFNγ, but also IL-4 
levels were higher in intermediate decliners compared to the slow decliners, indicating the 
heterogeneity in the AD population.  
Changes in peripheral immune cells occur in AD (Singh et al., 1986; Song et al., 1999). Shad 
et al. found that the levels of monocytes were higher in the serum of AD patients when 
compared to the normal range described for monocyte counts, and the AD patients with that 
showed normal counts of monocytes had higher levels of neutrophils (Shad et al., 2013). 
Other studies on the functional state of peripheral immune cells described increased levels of 
mitochondrial lipid peroxidation markers in leukocytes from MCI patients and an increase in 
mitochondrial oxidative stress proteins in leukocytes from both MCI and AD patients 
(Sultana et al., 2013). Blood transcriptome analysis of MCI and AD showed perturbation of 
mitochondria, ribosomes, and the immune system (Han et al., 2013). Elevation of 
mitochondrial stress markers in neutrophils (Vitte et al., 2004), increased activation of 
platelets (Casoli et al., 2010), and perturbation in phagocytic processes of macrophages (Fiala 
et al., 2005), have been reported to occur in AD. When comparing Aβ1-42 stimulated Th-1 
responses in healthy elderly subjects with healthy middle age and healthy young controls, the 
levels of IFNγ producing Th-1 responses declined progressively with age, whereas those of 
IL-10 increased (Loewenbrueck et al., 2010). Interestingly, IL-10 responses were higher in 
AD patients and in patients with Down syndrome compared to healthy elderly subjects. 
While IFNγ producing Th-1 responses was decreased in aged healthy controls, the same 
responses were diminished in AD patients and patients with Down syndrome (Loewenbrueck 
et al., 2010), indicating a failure in peripheral immune system in AD distinguished from that 
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of aging. Altogether these studies highlight the complexity of immunological changes in AD 
in which the failure is not only confined to the brain, but peripheral failures may also have 
substantial contribution.  
 
1.1.6 The dual nature of inflammation in Alzheimer disease 
Many of the mediators of inflammation, including IL1-β, IL-6, IL-10, and TNFα, are 
expressed in the brain, and at physiological levels play important roles in processes such as 
neurogenesis and in learning and memory (Erta et al., 2012; Estes & McAllister, 2014). It can 
be argued that an increase or decrease in the levels of inflammatory mediators may lead to 
pathological conditions or disturbance in brain function. Likewise, microglia in the brain 
display both pro-inflammatory and non-inflammatory functions. In normal conditions, 
“resting” microglia monitor the microenvironment and synapses by extending and retracting 
processes, and this surveillance function plays an important role in maintenance of brain 
homeostasis. It has been shown that microglia, in addition to its role in synapse remodelling, 
promote beneficial responses by inducing neurogenesis in the hippocampus and dentate 
gyrus, releasing growth factors, and phagocytosis of debris after stroke (Polazzi & Monti, 
2010). Increasing evidence suggest a complex role for inflammation in AD. Thus, in addition 
to the detrimental role of inflammatory mediators in AD as discussed in the previous chapter, 
the protective role of inflammation in AD is supported by other studies. Overexpression of 
IL-6 (Chakrabarty et al., 2010b) and IL-1β (Shaftel et al., 2007) in a mouse model for AD 
was shown to result in microglial activation and reduced amyloid deposition by enhancing 
phagocytosis (Chakrabarty et al., 2010b). Although the 3xTgAD mice (see section 1.3.1 and 
Table 1) exhibit increased levels of TNF-α, as also seen in AD, blocking of TNFα signalling 
by knocking out the cognate receptors for TNFα (TNFRI and TNFRII) in 3xTgAD mice was 
associated with increased amyloid deposition and enhanced tau phosphorylation 
(Montgomery et al., 2011). Moreover, microglia from TNFR deficient 3xTgAD mice showed 
defective phagocytosis, thus highlighting the protective role of TNFα in facilitating clearance 
mechanisms. In these studies, the elevated levels of inflammatory markers are present prior to 
AD-pathology, thus underscoring the impact of the temporal aspect on the detrimental or 
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beneficial outcome of inflammation. The inflammatory milieu could be another factor in 
determining the outcome of inflammation. The induction of Th-2 responses with elevated 
anti-inflammatory cytokine levels in an already established pro-inflammatory milieu in 
3xTgAD mice led to beneficial responses by offsetting the pro-inflammatory milieu (Jung et 
al., 2012). The pro-inflammatory cytokine IFNγ plays an important role in neurogenesis at 
physiological levels in brain. Although a decline in neurogenesis has been observed in 
wildtype and APP-Tg mice in an age-dependent manner, a moderate IFNγ overexpression in 
APP-Tg mice showed almost two-fold higher neurogenesis (Baron et al., 2008), suggesting 
that small increases in IFNγ could compensate for age-related decline in neurogenesis.     
Activation of complements occurs at early stages in AD and increases in advanced stages of 
the disease (Zanjani et al., 2005). The messenger ribonucleic acid (mRNA) levels of 
complement proteins were higher in brain than in liver, indicating local synthesis in the brain 
(Yasojima et al., 1999).  Analysis of post-mortem brain tissue from AD patients showed a 
significantly higher number of amyloid plaques associated with staining for MAC, and this 
correlated with synaptic loss (Lue et al., 1996), suggesting a detrimental role for complement. 
In contrast, the risk allele in CR1 associated with AD has an additional binding site for 
C3b/C4b, and may dampen the complement pathway and C3b mediated opsonisation and 
clearance of Aβ (Brouwers et al., 2012).  The protective role of complement in Aβ clearance 
and phagocytosis was reported in mouse models of AD. Blocking of the complement system 
by overexpression of soluble Crry (complement inhibitor in rodents) (Wyss-Coray et al., 
2002) or C3 deficiency (Maier et al., 2008) in a mouse model for AD increased the levels of 
Aβ, which was not due to increased production of Aβ but rather reflected the role of 
complement in the clearance mechanism. In the same studies, blocking complement was 
associated with decreased neuronal loss in the hippocampus. Both Crry overexpression and 
C3 deficiency leads to reduced levels of C5a. It is possible that the protective effect of 
complement blockage is due to reduced levels of C5a or hindering of MAC formation. This is 
supported by findings from 3xTgAD and Tg2576 mice in which anti-C5a antibodies 
decreased inflammation and improved behaviour (Fonseca et al., 2009), indicating the 
complex nature of immune processes. 
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Additional examples of the dual role of inflammation in AD could be derived from the 
clinical trials involving NSAIDs. Despite the reduced risk for developing AD associated with 
long-term medication with NSAIDs (McGeer et al., 1996), clinical trials in patients with 
established AD were not therapeutically beneficial (Leoutsakos et al., 2012). Leoutsakos et 
al. stratified the patients in the preclinical AD group that received naproxen or celecoxib into 
three phases based on their cognitive decline (Leoutsakos et al., 2012), meaning that patients 
with a fast decline in cognition probably would be closer to AD than those with little or no 
cognitive decline. Interestingly, naproxen was beneficial in fast decliners, but had no effects 
in non- or little decliners, or in slow decliners. In contrast, celecoxib was beneficial in slow 
decliners, but harmful in the fast decliners. Celecoxib is a selective inhibitor of 
cyclooxygenase (COX)-2, and its expression peaks in neurons in Braak phase (NFT) 0-II, 
probably representing an adaptive response, which subsequently declines (Hoozemans et al., 
2008). Thus, blocking of COX-2 in early phases may therefore be harmful whereas blocking 
of COX-1 by naproxen (in addition to COX-2) may be beneficial, since the microglial COX-
1 expression increases in later Braak phases III-IV (Hoozemans et al., 2008). Stratification of 
AD patients based on pro-inflammatory endotypes (PIE), which was characterized by plasma 
TNFα and CRP levels, showed that 12 months treatment with naproxen had a positive effect 
on cognition in the subset of patients with high baseline PIE, whereas opposite effects of the 
treatment were observed in those with low baseline PIE (O'Bryant et al.).  
 
1.2 Allergy 
1.2.1 Airway allergy - Overview 
Allergy is a chronic inflammatory disease, often with onset already during childhood or 
adolescence, affecting more than 20% of the Western population. Asthma, allergic rhinitis 
and atopic dermatitis are among the most commonly encountered chronic allergic diseases, 
often referred to as atopic disorders. More than 300 million people suffer from asthma 
worldwide and the global prevalence of asthma ranges from 1-18% in different countries 
(Bateman et al., 2008). Asthma is a heterogeneous disorder, the exact cause is not known but 
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genetic factors (atopy, history of asthma in the family), environmental factors (air pollution, 
viral infections, allergen exposure, occupational exposure), and life-style factors (food, 
smoking), influence the disease (Alberi, 2013).  
The allergic cascade crucial for development of asthma appears in three phases namely the 
induction phase, early phase and late phase. During the induction phase, the allergens enter 
the airways, are processed and brought to lymph nodes by antigen-presenting cells, and are 
presented to T- and B-cells. Activation of T-cells - especially Th-2 cells - leads to production 
of cytokines, and anti-inflammatory cytokines of which IL-4, IL-5, IL-9 and IL-13 are the 
most important in the development of asthma. IL-4 and IL-13 play a role in the development 
of IgE antibodies, IL-5 is important for the production and mobilization of eosinophils, and 
IL-9 is important for mast cell development. In the early phase, lasting between 30 and 60 
min, mast cells secrete inflammatory mediators (histamine, proteases, prostaglandins, 
leukotrienes, cytokines, growth factors) after activation by allergen, leading to constriction of 
airway smooth muscles, vascular leakage, mucus production, enhanced airway 
hyperresponsiveness, and recruitment of inflammatory cells. During the late phase reaction 4 
- 6 h later, activated Th-2 cells release IL-4, IL-5, and IL-13, with subsequent IgE isotype-
switching in B-cells, eosinophil activation, and release of pro-inflammatory mediators. 
Various cells such as eosinophils, neutrophils, dendritic cells, T-cells, macrophages, 
endothelial cells, airway smooth muscle cells, and bronchial epithelial cells, and the 
mediators released by these cells, contribute to airway remodelling i.e. airway wall 
thickening, subepithelial fibrosis, globlet cell hyperplasia, airway smooth muscle hyperplasia 
and hypertrophy, and epithelial hypertrophy (for review see (Bloemen et al., 2007; Diamant 
et al., 2013)).  
Extensive research in the field of asthma have led to subtyping the disease into endotypes 
(subtype of the disease with distinct pathogenic mechanisms), which could prove useful for 
designing therapies tailored to the individual’s biology. Agache et al. characterized five 
endotypes of asthma:  
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a) allergic asthma, often with onset at childhood, driven by Th-2 responses and 
recruitment of eosinophils in the airways; the presence or exposure to the allergen 
drives the Th-2 inflammation; is often steroid-responsive 
b) intrinsic (non-atopic) asthma, which represents one third of all adult asthmatics, 
shares similarities with allergic asthma, but with higher levels of the pro-
inflammatory cytokines IL-2 and IFNγ, but no change in IL-4 in the bronchoalveolar 
lavage (BAL) fluid; allergens have no obvious role in driving the inflammation; can 
be both steroid-responsive and steroid-resistant  
c) non-eosinophilic asthma, characterized by the presence of neutrophils in the airways 
instead of eosinophils; steroid-resistant 
d) aspirin-intolerant asthma; affects 5 - 10% of asthmatics, more common in non-atopic 
asthmatics with greater sensitivity to leukotrienes; steroid-responsive  
e) extensive remodelling asthma, characterized by minimal inflammation, but extensive 
airway remodelling, with production of angiogenic and lymphangiogenic factors; 
steroid-resistant (Agache et al., 2012)  
The response to existing asthma treatments, including β2-agonists and steroids, shows 
individual variation, and non-eosinophilic asthmatics usually respond poor to glucocorticoids. 
Treatment based on the underlying disease mechanism has proven efficient, for example in 
the case of anti-cytokine therapy with Mepolizumab (anti-IL-5 antibody) in severe asthmatics 
with persistent eosinophilia (Agache et al., 2012; Lin et al., 2013).   
 
1.2.2 Allergy and the brain 
There is a wide literature on the effects of systemic inflammation on the central nervous 
system (CNS) associated with bacterial and viral infections, generally accompanied by Th-1 
responses. However, studies on the effects of systemic inflammation associated with Th-2 
responses, such as allergic diseases, on the brain are emerging. It is clear that asthma 
symptoms are accentuated during periods of increased stress or emotions, and this was shown 
in a study of undergraduate asthmatics who, during the final examination week, showed 
larger airway inflammation and airway obstruction in response to allergen challenge, 
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compared to the stress-free period (Liu et al., 2002). In studies of food allergies, mice orally 
challenged with ovalbumin (OVA) showed increased anxiety-like behaviour as shown by the 
time spent in the open arms of elevated plus maze (EPM). The neural correlates for these 
behavioural changes included increased activity in specific brain regions; the paraventricular 
nucleus of the thalamus, the central nucleus of amygdala, and the nucleus of the solitary tract 
(Basso et al., 2003; Costa-Pinto et al., 2005). OVA-sensitized mice also showed preference 
for the otherwise aversive lit chamber, instead of the dark chamber where they were 
previously exposed to the allergen (Costa-Pinto et al., 2007). In human asthmatics, asthma-
specific words induced increased activity in the anterior insular cortex (AIC), following 
allergen challenge. The AIC activity correlated with increase in the number of eosinophils in 
the sputum (disease severity) (Rosenkranz et al., 2012). Hypoxia resulting from asthma may 
have secondary effects on brain and cognition (Alberi, 2013).   
The components of the nervous system (sympathetic, parasympathetic and sensory) can 
modulate the immune processes involved in the development of allergic reaction, either 
directly or indirectly. For example, the sympathetic nervous system (SNS) modulates antigen 
uptake and processing in dendritic cells (DCs) through adrenergic receptors expressed on 
DCs. Similarly, the SNS modulates Th-1 and Th-2 balance in T-cells towards an anti-
inflammatory profile and enhance humoral responses by increasing Ig production from B-
cells (Forsythe, 2012). Immune cells such as eosinophils, neutrophils and macrophages, but 
also endothelial cells, express nicotinic acetylcholine receptors (AChRs), through which the 
parasympathetic nervous system exerts its anti-inflammatory action (Kolahian & Gosens, 
2012). Thus, it is not surprising that stress exacerbates the course of disorders such as asthma 
and AD in which inflammation is associated with its pathogenesis. Peripheral sensory 
neurons regulate inflammation locally by modulating the responses in immune cells through 
release of neuropeptides such as substance P, neuropeptide Y and vasoactive intestinal 
polypeptide (Forsythe, 2012). Interestingly, neurons have been shown to express receptors 
for Igs, supporting the idea that the cross-talk between the immune and nervous system is 
bidirectional. Dorsal root ganglion (DRG) neurons express high affinity receptors for IgG 
(FcγRI or CD64) and for IgE (FcεRI) (Andoh & Kuraishi, 2004b). The formation of IgG-
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antigen complex on sensitized DRG neurons induced an increase in intracellular calcium 
levels and the release of substance P from these neurons (Andoh & Kuraishi, 2004a). 
Furthermore, it was shown that sensitized DRG neurons not only bound IgE, but also Ig light 
chain (IgLC), and that IgLC-binding increased the intracellular calcium levels (Rijnierse et 
al., 2009).  
   
1.2.3 Allergy and Alzheimer disease 
The first report that investigated the association between atopic allergic diseases (allergic 
rhinitis, allergic dermatitis, and allergic asthma) and AD showed that atopy was associated 
with a 16% increase in the risk for AD (Eriksson et al., 2008). In addition, asthma was 
associated with reduction in survival time. Subjects with asthma lived on average 1.8 years 
less than non-asthmatics (Eriksson et al., 2008). Subsequent epidemiological studies on 
airway disorders, such as asthma and chronic obstructive pulmonary disorders (COPD), in 
the elderly have shown a positive association to cognitive impairment and/or dementia 
(Rusanen et al., 2013; Singh et al., 2013; Chen et al., 2014; Peng et al., 2014; Singh et al., 
2014). Rusanen et al. found that mid-life (age range 39 - 64 years) asthma and COPD, 
respectively, were associated with an almost two-fold increase in the risk for cognitive 
impairment, whereas late-life (age range 65 - 80 years) diagnosed asthma and COPD were 
associated with reduced risk (Rusanen et al., 2013). However, in the study of Chen et al., 
although asthma was associated with a more than two-fold increase in the risk for developing 
any dementia or AD, subgroup analysis showed that both mid- (age range 45 - 64 years) and 
late-life (≥ 65 years) asthma were associated with almost two-fold increase in risk for any 
dementia, whereas only late-life asthma was associated with almost three-fold increase in risk 
for AD (Chen et al., 2014). Other factors, such as asthma exacerbations (Peng et al., 2014) or 
duration of COPD (Singh et al., 2013), were associated with an increased risk for MCI. The 
mechanisms of interaction between allergic diseases and AD have not been studied. As 
discussed above, allergic diseases are heterogeneous, with different inflammatory profiles, 
and consequently the interaction of allergy with AD can be very complex.  
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1.2.4 Neuroimmune communication  
Following systemic infection, the body activates the innate immune response by inducing the 
production of inflammatory mediators such as cytokines, chemokines, and prostaglandins at 
the site of infection to eliminate the pathogen. This response is followed by production of 
other mediators that promote phagocytosis of the pathogen and debris, and induce repair to 
re-establish homeostasis. If the inflammation is unresolved by innate immunity, the body 
mounts up the adaptive immune response, which in contrast to innate immunity, is highly 
specific and involves activation of T- and B-cells.   
The neuroimmune communication and the impact of systemic inflammatory responses – for 
example induced by bacterial or viral antigens – on the brain has been studied extensively. 
Peripherally produced cytokines such as IL-1β, IL-6 and TNFα, in response to LPS infection 
have been shown to induce sickness behaviour i.e. fever, nausea, reduced appetite, loss of 
interest in social and physical activity, fatigue, and fragmented sleep (Dantzer et al., 2008).  
Systemic administration of lipopolysaccharide (LPS) was shown to increase the production of 
IL-1β and TNFα and other inflammatory mediators in the brain (van Dam et al., 1992; Laye 
et al., 1994; Quan et al., 1999; Eriksson et al., 2000). Several pathways are implicated in 
facilitating neuroimmune communication. One pathway involves the activation of the vagus 
nerve by locally produced cytokines. The second pathway is through activation of resident 
macrophages in circumventricular organs (CVOs). As these structures do not have a BBB, 
the pro-inflammatory cytokines produced by macrophages could enter the brain parenchyma. 
The third pathway involves the transport of cytokines (excessively produced) across the BBB 
by means of saturable transport systems (Dantzer et al., 2008). In the fourth pathway, the 
activation of IL-1 receptors on perivascular macrophages and endothelial cells of brain 
venules, by circulating cytokines, leads to production of prostaglandins (E2 series) that 
diffuse into the brain, and play role in activation of hypothalamic pituitary axis and cytokine 
induced fever (Konsman et al., 2002; Dantzer et al., 2008).  
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1.3 Animal models 
1.3.1 Mouse models for Alzheimer disease 
Several types of transgenic (Tg) mouse models for AD have been developed by 
incorporation of human genes with FAD mutations into the mouse genome. The 
neuropathological features of some of the commonly used Tg strains are presented in Table 
1. Although manifestation of AD-like pathology and related pathological processes occur at 
different time points (see Table 1), the bottom line is that the Tg mice mirror some features 
of human AD including amyloid accumulation, abnormal hyperphosphorylation of tau, 
neuroinflammation, cognitive deficits, and impairment of synaptic plasticity. Development 
of amyloid pathology differs from strain to strain, and aspects including number and types 
of FAD mutations incorporated into the mouse genome, site of integration in the 
deoxyribonucleic acid (DNA), type of promoter driving the gene expression, and the 
genetic background of mice may contribute to some of the observed differences. Moreover, 
the isoforms of APP used for overexpression may account for some differences. Although 
the APP695 isoform is predominantly expressed by neuronal cells in the brain, Kunitz-type 
serine protease inhibitor-containing isoforms of APP (APP751) is found on glial cells and a 
slight increase in APP751 with aging has been reported in humans (though not on glial 
cells), and may play a role in amyloid formation (Rockenstein et al., 1995). The expression 
levels of human APP differ between the strains (See Table 1), and several studies show an 
association between transgene expression levels and development of plaque pathology 
(Sturchler-Pierrat et al., 1997; Chishti et al., 2001; Ronnback et al., 2011). Although, none 
of the Tg mice represent the full spectrum of human AD, they have been important in vivo 
tools for studying AD pathogenesis, to provide insights into disease mechanism, and to 
evaluate disease-modifying therapies and biomarkers. An ideal AD model should mimic 
most, if not all, aspects of AD that include the pathogenesis of the disease i.e its etiology 
and progression of the pathology. The available animal models for AD suffer from major 
limitations: (i) sporadic AD accounting for more than 95% of AD cases, does not have 
familial mutations, (ii) mouse models for AD do not show neurodegeneration – a 
substantial hallmark in AD, (iii) the tangle pathology – another hallmark of AD – is absent 
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in these mice despite the presence of hyperphosphorylated tau, unless the tangle pathology 
is driven by a mutated tau gene (3xTgAD and APPSWE-Tau) that is not present in human 
AD. In conclusion, mouse models for AD are mostly models of amyloidosis, raising major 
concerns when extrapolating data from models to human conditions, and may probably 
explain why the majority of compounds proving successful in Tg mice failed in human 
trials (for review see (Franco & Cedazo-Minguez, 2014)). Nevertheless, a new rat model of 
AD developed on mutant APP and PS1 genes, showed age-related amyloidosis, tangle 
pathology, gliosis, behavioural deficits, and neuronal loss in hippocampus and cortex, and 
may offer a more human-like model of AD, compared to mouse models (Cohen et al., 
2013).  
 
1.3.2 Mouse models for asthma 
Asthma is a predominantly human disorder although cats and horses develop airway allergy 
analogous to the human condition (Mullane & Williams, 2014). Models of asthma, acute 
and/or chronic, have been developed in several species including rodents and non-human 
primates (Mullane & Williams, 2014; Mercer et al., 2015), but the most commonly used 
and extensively investigated model is the OVA-mouse model based on (i) sensitization to 
and (ii) subsequent airway challenge with the allergen, namely OVA. The nature of 
inflammatory response, and the development of associated changes, depend on several 
factors including choice of strain, route and dose of sensitization, the nature of adjuvant, the 
type of allergen, and the route and duration of the challenge (Kumar et al., 2008). The route 
of sensitization influences the strength of the immunological response since mice sensitized 
intraperitoneally (i.p.) showed higher levels of allergen-specific IgE levels compared to 
intranasal or mucosal sensitization (Zhang et al., 1997; Zhu & Gilmour, 2009). An 
adjuvant, such as aluminum hydroxide (Al(OH)3), is used to boost the humoral immunity 
towards Th-2 skewing (Eisenbarth et al., 2008; Kool et al., 2008), one of the features of 
allergic (atopic) asthma (Agache et al., 2012). The mouse strains affect the type of allergic 
inflammation in terms of cytokine profile, immune responses and airway responsiveness 
(Zhang et al., 1997; Zhu & Gilmour, 2009; Kelada et al., 2011). For instance, increased 
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levels of eosinophils are found in the BAL of Balb/c mice following allergy, while an 
increase in neutrophils in addition to eosinophils is found in C57BL6 mice (Whitehead et 
al., 2003; Sarlus et al., 2012). Furthermore, other intrinsic differences between the strains 
such as alveolar size (Soutiere et al., 2004) and lung mechanics (Tankersley et al., 1999), 
may also affect the nature of allergic inflammation.  
The OVA-mouse models have played a pivotal role in investigating the molecular 
mechanism of allergic inflammation by recapitulating significant clinical feature of human 
asthma including lung eosinophilia, Th-2 driven cytokines (IL-4, IL-5, IL-13), increased 
mast cell activation, airway hyperresponsiveness and remodelling (Mercer et al., 2015). 
Despite showing patterns of human-like asthma and responding positively to 
glucocorticoids and to β2-receptor agonists, the models of asthma have substantially failed 
in translating to human conditions (Mercer et al., 2015), most likely due to the 
heterogeneous nature of asthma, with several phenotypes with different etiology and 
distinct cellular and molecular mechanisms (Agache et al., 2012). Airway inflammation in 
intrinsic asthma shares similarities with allergic asthma – often with onset in childhood – 
but IL-2, IFNγ and not IL-4 are increased in the BAL fluid, whereas neutrophilic asthma – 
often with adult onset  – is characterized by the absence of eosinophilia and increased Th-
17 response (Agache et al., 2012). Thus, extrapolating to a heterogeneous disorder such as 
asthma from mouse models that largely represent the allergic/eosinophilic phenotype 
(Kumar & Foster, 2012), can possibly succumb into failure. In order to increase the success 
for translation, the model used should be appropriate for the outcome that is being studied 
(Kumar & Foster, 2012; Mercer et al., 2015). For example differences at the molecular 
level, such as β1-receptor predominance on mouse airways compared to β2-receptor in 
humans, or different subsets of mediators released by mast cells of mouse vs human, may 
influence outcomes for the translation approaches (Mercer et al., 2015). Thus, guinea pigs 
will be a suitable model for studying outcomes involving β-receptors in airways compared 
to mice (Mercer et al., 2015).  
 
 21 
levels of eosinophils are found in the BAL of Balb/c mice following allergy, while an 
increase in neutrophils in addition to eosinophils is found in C57BL6 mice (Whitehead et 
al., 2003; Sarlus et al., 2012). Furthermore, other intrinsic differences between the strains 
such as alveolar size (Soutiere et al., 2004) and lung mechanics (Tankersley et al., 1999), 
may also affect the nature of allergic inflammation.  
The OVA-mouse models have played a pivotal role in investigating the molecular 
mechanism of allergic inflammation by recapitulating significant clinical feature of human 
asthma including lung eosinophilia, Th-2 driven cytokines (IL-4, IL-5, IL-13), increased 
mast cell activation, airway hyperresponsiveness and remodelling (Mercer et al., 2015). 
Despite showing patterns of human-like asthma and responding positively to 
glucocorticoids and to β2-receptor agonists, the models of asthma have substantially failed 
in translating to human conditions (Mercer et al., 2015), most likely due to the 
heterogeneous nature of asthma, with several phenotypes with different etiology and 
distinct cellular and molecular mechanisms (Agache et al., 2012). Airway inflammation in 
intrinsic asthma shares similarities with allergic asthma – often with onset in childhood – 
but IL-2, IFNγ and not IL-4 are increased in the BAL fluid, whereas neutrophilic asthma – 
often with adult onset  – is characterized by the absence of eosinophilia and increased Th-
17 response (Agache et al., 2012). Thus, extrapolating to a heterogeneous disorder such as 
asthma from mouse models that largely represent the allergic/eosinophilic phenotype 
(Kumar & Foster, 2012), can possibly succumb into failure. In order to increase the success 
for translation, the model used should be appropriate for the outcome that is being studied 
(Kumar & Foster, 2012; Mercer et al., 2015). For example differences at the molecular 
level, such as β1-receptor predominance on mouse airways compared to β2-receptor in 
humans, or different subsets of mediators released by mast cells of mouse vs human, may 
influence outcomes for the translation approaches (Mercer et al., 2015). Thus, guinea pigs 
will be a suitable model for studying outcomes involving β-receptors in airways compared 
to mice (Mercer et al., 2015).  
 22
 
Ta
ble
. 1
 C
ha
rac
ter
ist
ics
 of
 so
me
 of
 th
e c
om
mo
nly
 us
ed
 T
g m
ou
se 
mo
de
ls 
for
 A
D 
Na
me
 
Tr
an
sg
en
e 
Pr
om
ote
r 
AP
P 
ex
pr
ess
ion
 
lev
el 
 
Am
ylo
id 
pa
th
olo
gy
 
Ta
u p
ath
olo
gy
 
Gl
ios
is 
Co
gn
iti
ve
 
im
pa
irm
en
t 
Sy
na
pt
ic 
los
s 
Pr
im
ar
y 
Re
fer
en
ce
 
3x
Tg
AD
 
AP
P6
95
 
(K
67
0N
/M
67
1L
)  P
S1
 
(M
14
6V
) T
au
 (P
30
1L
) 
Th
y1
.2 
6-8
-fo
ld 
6 m
on
ths
 
12
 m
on
ths
 
Ye
s 
4 m
on
ths
 
Un
kn
ow
n 
(O
dd
o e
t a
l., 
20
03
) 
Tg
25
76
 
AP
P6
95
 (K
67
0N
/M
67
1L
) 
Ha
ms
ter
 Pr
P 
6-f
old
 
11
 - 1
3 m
on
ths
 
Ab
sen
t 
Ye
s 
10
 - 1
6 m
on
ths
 
6 -
 12
 m
on
ths
 
4.5
 m
on
ths
 
(H
sia
o e
t a
l., 
19
96
) 
AP
PS
we
-T
au
 
AP
P6
9 (
K6
70
N/
M
67
1L
)  
Ta
u (
P3
01
L)
 
Ha
ms
ter
 Pr
P 
Sim
ila
r a
s 
Tg
25
76
 
6 -
 7 
mo
nth
s 
3 -
 6 
mo
nth
s 
Ye
s 
3 m
on
ths
 
Un
kn
ow
n 
Un
kn
ow
n 
(L
ew
is 
et 
al.
, 
20
01
) 
5x
FA
D 
1s
t tr
an
sg
en
e: 
hA
PP
69
5 (
K6
70
N/
M
67
1L
) 
(S
we
) I
17
6V
(F
lor
ida
) V
71
7I 
(L
on
do
n) 
 2n
d t
ran
sg
en
e 
hP
S1
 M
14
6L
 L
26
6V
 
Th
y 1
 
 
1.5
 - 2
 m
on
ths
 
Ab
sen
t 
Ye
s 
4 -
 5 
mo
nth
s 
Ye
s 
Pr
og
res
siv
e 
9 -
 12
 
mo
nth
s 
+ N
eu
ron
al 
los
s 
(O
ak
ley
 et
 al
., 
20
06
) 
Tg
CR
ND
8 
hA
PP
96
5 
(K
67
0N
/M
67
1L
) (
Sw
e) 
V7
17
F  
Ind
ian
a 
Ha
ms
ter
 Pr
P  
5-f
old
 
3 m
on
ths
 
Ab
sen
t 
p-t
au
 at
 7 
- 1
2 
mo
nth
s 
Ye
s 
2.5
 - 3
 m
on
ths
 
3 m
on
ths
 
 
(C
his
hti
 et
 al
., 
20
01
) 
AP
PP
S1
 
hA
PP
69
5 
(K
67
0N
/M
67
1L
) 
PS
1 (
l16
6P
) 
Th
y 1
 
3-f
old
 
1.5
 m
on
ths
 
Ab
sen
t. 
p-t
au
 po
sit
ive
 
ne
uri
tes
 ob
ser
ve
d 
Ye
s 
1.5
 m
on
ths
 
7 -
 8 
mo
nth
s 
Ye
s 
4 m
on
ths
 
Ne
uro
na
l 
los
s a
t 1
7 
mo
nth
s 
(R
ad
de
 et
 al
., 
20
06
) 
AP
P2
3 
hA
PP
75
1 
(K
67
0N
/M
67
1L
) 
 
Th
y 1
 
7-f
old
 
6 m
on
ths
 
Ab
sen
t. 
p-t
au
 po
sit
ive
 
ne
uri
tes
 ob
ser
ve
d 
Ye
s 
As
so
cia
ted
 
wi
th 
pla
uq
es 
at 
6 m
on
ths
 
3 m
on
ths
 
Ne
uro
na
l 
los
s 1
4 -
 18
 
mo
nth
s  
Sy
na
pti
c 
los
s a
bs
en
t 
at 
as 
old
 as
  
24
 m
on
ths
 
(S
tur
ch
ler
-
Pie
rra
t e
t a
l., 
19
97
) 
Tg
-A
rc-
Sw
e 
hA
PP
69
5 
(K
67
0N
/M
67
1L
) 
(E
69
3G
) 
Th
y 1
.2 
3-f
old
 
5 -
 6 
mo
nth
s 
Ab
sen
t 
Ye
s 
4 -
 8 
mo
nth
s 
Un
kn
ow
n 
(L
ord
 et
 al
., 
20
06
) 
PD
AP
P  
(li
ne
 10
9) 
hA
PP
 69
5, 
75
1, 
77
0 
V7
17
F (
Ind
ian
a) 
 
  
hP
DG
F-
β 
10
-fo
ld 
6 m
on
ths
 
Ab
sen
t  
p-t
au
 at
 14
 m
on
ths
 
Ye
s 
ass
oc
iat
ed
 w
ith
 
pla
qu
es 
3 m
on
ths
 
Sy
na
pti
c 
los
s 
pre
sen
t a
t 8
 
mo
nth
s  
(G
am
es 
et 
al.
, 
19
95
) 
 
22
 
Ta
ble
. 1
 C
ha
rac
ter
ist
ics
 of
 so
me
 of
 th
e c
om
mo
nly
 us
ed
 T
g m
ou
se 
mo
de
ls 
for
 A
D 
Na
me
 
Tr
an
sg
en
e 
Pr
om
ote
r 
AP
P 
ex
pr
ess
ion
 
lev
el 
 
Am
ylo
id 
pa
th
olo
gy
 
Ta
u p
ath
olo
gy
 
Gl
ios
is 
Co
gn
iti
ve
 
im
pa
irm
en
t 
Sy
na
pt
ic 
los
s 
Pr
im
ar
y 
Re
fer
en
ce
 
3x
Tg
AD
 
AP
P6
95
 
(K
67
0N
/M
67
1L
)  P
S1
 
(M
14
6V
) T
au
 (P
30
1L
) 
Th
y1
.2 
6-8
-fo
ld 
6 m
on
ths
 
12
 m
on
ths
 
Ye
s 
4 m
on
ths
 
Un
kn
ow
n 
(O
dd
o e
t a
l., 
20
03
) 
Tg
25
76
 
AP
P6
95
 (K
67
0N
/M
67
1L
) 
Ha
ms
ter
 Pr
P 
6-f
old
 
11
 - 1
3 m
on
ths
 
Ab
sen
t 
Ye
s 
10
 - 1
6 m
on
ths
 
6 -
 12
 m
on
ths
 
4.5
 m
on
ths
 
(H
sia
o e
t a
l., 
19
96
) 
AP
PS
we
-T
au
 
AP
P6
9 (
K6
70
N/
M
67
1L
)  
Ta
u (
P3
01
L)
 
Ha
ms
ter
 Pr
P 
Sim
ila
r a
s 
Tg
25
76
 
6 -
 7 
mo
nth
s 
3 -
 6 
mo
nth
s 
Ye
s 
3 m
on
ths
 
Un
kn
ow
n 
Un
kn
ow
n 
(L
ew
is 
et 
al.
, 
20
01
) 
5x
FA
D 
1s
t tr
an
sg
en
e: 
hA
PP
69
5 (
K6
70
N/
M
67
1L
) 
(S
we
) I
17
6V
(F
lor
ida
) V
71
7I 
(L
on
do
n) 
 2n
d t
ran
sg
en
e 
hP
S1
 M
14
6L
 L
26
6V
 
Th
y 1
 
 
1.5
 - 2
 m
on
ths
 
Ab
sen
t 
Ye
s 
4 -
 5 
mo
nth
s 
Ye
s 
Pr
og
res
siv
e 
9 -
 12
 
mo
nth
s 
+ N
eu
ron
al 
los
s 
(O
ak
ley
 et
 al
., 
20
06
) 
Tg
CR
ND
8 
hA
PP
96
5 
(K
67
0N
/M
67
1L
) (
Sw
e) 
V7
17
F  
Ind
ian
a 
Ha
ms
ter
 Pr
P  
5-f
old
 
3 m
on
ths
 
Ab
sen
t 
p-t
au
 at
 7 
- 1
2 
mo
nth
s 
Ye
s 
2.5
 - 3
 m
on
ths
 
3 m
on
ths
 
 
(C
his
hti
 et
 al
., 
20
01
) 
AP
PP
S1
 
hA
PP
69
5 
(K
67
0N
/M
67
1L
) 
PS
1 (
l16
6P
) 
Th
y 1
 
3-f
old
 
1.5
 m
on
ths
 
Ab
sen
t. 
p-t
au
 po
sit
ive
 
ne
uri
tes
 ob
ser
ve
d 
Ye
s 
1.5
 m
on
ths
 
7 -
 8 
mo
nth
s 
Ye
s 
4 m
on
ths
 
Ne
uro
na
l 
los
s a
t 1
7 
mo
nth
s 
(R
ad
de
 et
 al
., 
20
06
) 
AP
P2
3 
hA
PP
75
1 
(K
67
0N
/M
67
1L
) 
 
Th
y 1
 
7-f
old
 
6 m
on
ths
 
Ab
sen
t. 
p-t
au
 po
sit
ive
 
ne
uri
tes
 ob
ser
ve
d 
Ye
s 
As
so
cia
ted
 
wi
th 
pla
uq
es 
at 
6 m
on
ths
 
3 m
on
ths
 
Ne
uro
na
l 
los
s 1
4 -
 18
 
mo
nth
s  
Sy
na
pti
c 
los
s a
bs
en
t 
at 
as 
old
 as
  
24
 m
on
ths
 
(S
tur
ch
ler
-
Pie
rra
t e
t a
l., 
19
97
) 
Tg
-A
rc-
Sw
e 
hA
PP
69
5 
(K
67
0N
/M
67
1L
) 
(E
69
3G
) 
Th
y 1
.2 
3-f
old
 
5 -
 6 
mo
nth
s 
Ab
sen
t 
Ye
s 
4 -
 8 
mo
nth
s 
Un
kn
ow
n 
(L
ord
 et
 al
., 
20
06
) 
PD
AP
P  
(li
ne
 10
9) 
hA
PP
 69
5, 
75
1, 
77
0 
V7
17
F (
Ind
ian
a) 
 
  
hP
DG
F-
β 
10
-fo
ld 
6 m
on
ths
 
Ab
sen
t  
p-t
au
 at
 14
 m
on
ths
 
Ye
s 
ass
oc
iat
ed
 w
ith
 
pla
qu
es 
3 m
on
ths
 
Sy
na
pti
c 
los
s 
pre
sen
t a
t 8
 
mo
nth
s  
(G
am
es 
et 
al.
, 
19
95
) 
  23 
In addition, the branching pattern of the lungs in mice, and the diameter of the airways in 
relation to the body size differ substantially between mice and humans (Kumar et al., 
2008). Despite such differences, the mouse models for asthma have yielded valuable 
information regarding the pathogenesis of asthma.   
In conclusion, animal models are valuable tools for studying in vivo mechanisms as long as 
we are aware of their limitations and the heterogeneous nature of the disease we are 
investigating. Different features of the disease are presented by different models, e.g. the 
Tg2576 model for AD (Hsiao et al., 1996) can serve as a good model for studying 
amyloidosis, whereas 3xTgAD mice (Oddo et al., 2003) can also allow for studying tau 
pathology (but not AD-like tau pathology). Similarly, mouse models of asthma show 
features that are relevant for the eosinophilic or allergic asthma phenotype in humans 
(Kumar & Foster, 2012). Thus, one could argue (in our case) that the “true” effects of 
asthma on AD pathogenesis may (i) depend on and (ii) possibly be limited to those aspects 
of disease that are represented by our model.   
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2 AIMS 
The main aim of this thesis was to study the effects of peripheral inflammation associated 
with allergy on the brain in presence or absence of AD-like pathology.   
The specific aims were to investigate:  
Paper I the effects of airway-associated allergy on inflammatory markers and AD-
related proteins in the brain using naive mice. 
Paper II the effects of airway-associated allergy on gene expression in the brain of 
naive mice. 
Paper III the effects of airway-associated allergy on the brain with regard to 
inflammatory markers, AD-related proteins, and behaviour using 3xTgAD 
mice and their background strain.   
Paper IV whether presence of allergy influences the levels of immunoglobulin classes, 
and the levels of pro- and anti-inflammatory cytokines, in the CSF and serum 
from patients with AD, MCI, and subjective cognitive impairment (SCI). 
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3 METHODOLOGY 
The detailed description of the experimental procedures used in Paper I-IV is provided in 
the respective paper. In this section, methods will be summarized with a brief account of 
the advantages and limitations for some of the models and methods.  
 
3.1 Methods for studying the pathogenesis of Alzheimer disease  
3.1.1 Mouse models  
We have used male mice in all studies, which may show less variation compared to female 
mice due to hormonal changes. However, variation is unavoidable because male mice, by 
nature, will establish hierarchy and the less dominant mice will be more stressed. Balb/c 
mice (Paper I) are good Th-2 responders and were used for development and validation of 
the allergy protocol but further analyses were performed in C57BL6 strain (Paper I, II), 
which is used as background strain for many transgenic animals. 3xTgAD mice and age-
matched male wildtype hybrid mice B6129SF1/J (Bg) were used in Paper III. The 
3xTgAD mice (Oddo et al., 2003) carry transgenes encoding mutated human amyloid 
APPSwe and tauP301L on PS1M146V knock-in background (see Table 1). The mice show 
intraneuronal Aβ and increased inflammation in entorhinal cortex at the age of three 
months (Janelsins et al., 2005) and develop amyloid plaques and tangles at the age of six 
and twelve months, respectively (Oddo et al., 2003). Behavioural characterization of these 
mice has revealed that memory deficits appear already at three months of age (Billings et 
al., 2005b) and at six months 3xTgAD mice show increased anxiety-like behaviour 
(Gimenez-Llort et al., 2007). We chose the 3xTgAD model in order to study the effects of 
allergy on both Aβ and tau phosphorylation as these mice develop both pathologies. For 
comments on validity of the AD mouse model, see section 1.3.1.   
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3.1.2 Human subjects 
In addition to mouse models, we have analysed (Paper IV) samples obtained from SCI, 
MCI, and AD (see Introduction) cases.  
  
3.1.2.1 Subjective cognitive impairment 
SCI is defined by memory complains and is common in elderly (Jessen et al., 2007). 
However, these patients do not show impairment on objective cognitive task, but some 
probably represent an early stage prior to developing MCI. Recently, it was shown that 
individuals with SCI who were experiencing memory problems had a higher risk to develop 
AD compared to those without memory problems, and the risk was similar to those of early 
MCI (Jessen et al., 2014). Patients with SCI represent an interesting study population and 
longitudinal follow-up of these patients may provide opportunities to reveal early changes 
associated with AD.   
 
3.1.2.2 Mild cognitive impairment   
Subjects with MCI were diagnosed according to following criteria (Winblad et al., 2004):   
• Not normal, not demented (does not meet criteria in the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV), and the International 
Classification of Mental and Behavioural Disorders (ICD-10) for dementia 
syndrome) 
• Cognitive decline reported by the patient or informant and measurable impairment 
objectively on cognitive tasks or evidence of decline on objective cognitive tasks   
• Preserved basic activities of daily living with minimal impairment in complex 
instrumental functions.   
In the modified criteria (Albert et al., 2011), the assessment of biomarkers (such as CSF 
and imaging) is incorporated for the research criteria, which makes MCI a valuable source 
to study early changes in the course of AD. However, there are limitations with the use of 
 
26 
3.1.2 Human subjects 
In addition to mouse models, we have analysed (Paper IV) samples obtained from SCI, 
MCI, and AD (see Introduction) cases.  
  
3.1.2.1 Subjective cognitive impairment 
SCI is defined by memory complains and is common in elderly (Jessen et al., 2007). 
However, these patients do not show impairment on objective cognitive task, but some 
probably represent an early stage prior to developing MCI. Recently, it was shown that 
individuals with SCI who were experiencing memory problems had a higher risk to develop 
AD compared to those without memory problems, and the risk was similar to those of early 
MCI (Jessen et al., 2014). Patients with SCI represent an interesting study population and 
longitudinal follow-up of these patients may provide opportunities to reveal early changes 
associated with AD.   
 
3.1.2.2 Mild cognitive impairment   
Subjects with MCI were diagnosed according to following criteria (Winblad et al., 2004):   
• Not normal, not demented (does not meet criteria in the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV), and the International 
Classification of Mental and Behavioural Disorders (ICD-10) for dementia 
syndrome) 
• Cognitive decline reported by the patient or informant and measurable impairment 
objectively on cognitive tasks or evidence of decline on objective cognitive tasks   
• Preserved basic activities of daily living with minimal impairment in complex 
instrumental functions.   
In the modified criteria (Albert et al., 2011), the assessment of biomarkers (such as CSF 
and imaging) is incorporated for the research criteria, which makes MCI a valuable source 
to study early changes in the course of AD. However, there are limitations with the use of 
  27 
MCI as prodromal stage for AD. MCI represents a very heterogeneous group (Winblad et 
al., 2004), not only due to etiological reasons, but also there may be subgroups in MCI with 
different conversion rates to AD. When dividing MCI groups into late and early MCI, the 
former was associated with higher risk for developing AD (Jessen et al., 2014). Thus, there 
is a need for “markers”, which could allow stratification of this group in order to achieve a 
more homogenous subgroup. MCI constitute a very interesting study population for the 
detection of early changes associated with AD.   
 
Fig. 1. Mice were given intraperitoneal (i.p.) injection of ovalbumin (OVA) on day 0 and day 12 
and subsequently challenged intranasally. The black arrows indicate days. In study III (indicated by 
blue lines), behavioural tests including borrowing, elevated plus maze (EPM), open field (OF), and 
passive avoidance (PA) were performed on the indicated gaps when mice were not challenged with 
OVA. Samples were collected 24 h after the last challenge as indicated by the red circle.    
 
3.2 Experimental protocols in vivo 
3.2.1 Allergy provocation protocol 
All the mice were subjected to the chronic airway allergy protocol based on OVA 
sensitization followed by OVA-challenge (see Section 1.3.2). Briefly, mice were sensitized 
by receiving an i.p. injection of 200 µl suspension containing 10 μg OVA diluted in 4 
mg/ml Al(OH)3 in phosphate-buffered saline (PBS)-alum on day 0 and 12. The animals 
were challenged daily from day 18 to day 23, and then 3 times per week during an 
additional 5-week (Paper I, II) or 6-week (Paper III) period, by intranasal instillation of 
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100 μg OVA diluted in 50 μl PBS-alum (Fig. 1). Intranasal instillation was performed 
under light anesthesia with a controlled flow of 4% isoflurane and 96% O2, using a 
Univentor 400 anesthesia unit. Control animals underwent the same treatment but received 
PBS-alum instead of OVA.  
 
3.2.2 Behavioural studies  
A battery of behavioural tests (Paper III) was chosen to assess the effects of allergy-induced 
inflammation on emotionality/anxiety-like behaviour (i.e. elevated plus maze (EPM), open 
field (OF)) and hippocampus-dependent behaviour (i.e. EPM, burrowing, passive avoidance 
(PA)), (see (Billings et al., 2005a; Cunningham et al., 2009)). The behavioural tests 
considered least stressful, and presumably giving less long-lasting effects to the animal, were 
performed first (i.e. burrowing), while more stressful tests were performed at the end (i.e. 
passive avoidance). The tests were performed in the order described below.  
 
3.2.2.1 Burrowing test 
The burrowing test assesses a typical behaviour for rodents and consists of digging. The 
substrate offered for digging is a higher quantity of pelleted food, which the animal naturally 
tends to remove from the tube it is presented in. Cytotoxic lesions in hippocampus and 
prefrontal cortex (to lesser extent) in mice reduces the burrowing activity (Deacon, 2006). 
Systemic inflammation induced by LPS at sub-pyrogenic levels has been shown to decrease 
the burrowing activity (Teeling et al., 2007). Approximately 2 h prior to the start of the dark 
phase, the mice were placed individually in a cage with a burrowing tube containing 200 g 
food pellets. The quantity of food pellets displaced after 2 h and after the dark phase (approx. 
16 h) was calculated by weighing the pellets that remained in the tube (displaced food = total 
food - remaining food).  
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3.2.2.2 Elevated plus maze 
EPM test is a classical test for the assessment of anxiety-like behaviour in rodents (File et al., 
2005). The test was developed to provide a measure of anxiety that was unaffected by 
changes in overall motor activity. In EPM, opposition is created between the natural desire of 
the mouse to explore novel environment (positive motivation to enter the open arm) and the 
aversion to open areas (negative motivation to enter the open arm) in the apparatus. The EPM 
apparatus consisted of plus-shaped maze with two of the arms protected by transparent walls 
designating the close arms of the maze while the other two arms served as open arms. The 
maze was located 40 cm above the ground so that the “open arms combine the elements of 
unfamiliarity, openness and elevation” (File, 2001). The height above the floor is important 
because mice could jump off the maze if it is close to the ground. The EPM provides 
measures of two independent factors. The % of entries to open arms (number of open arms 
visits in relation to total number of entries on close and open arms) and % of time spent in 
open arms (time spent in open arms in relation to total time spent on close and open arms) 
reflected the measures of anxiety. On the other hand, the numbers of entries to the close arm 
and total arm entries reflected the measure of motor activity (File, 2001). Although the 
intensity of light affects the performance in OF, EPM does not rely on aversion to bright light 
(File et al., 2005).   
 
3.2.2.3 Open field  
The OF test is a classical test in which the behaviour of the mouse is dependent on variables 
such as locomotor function, exploratory drive and the fear/anxiety-like state (Stanford, 2007). 
The problem with OF is that it cannot differentiate between which variables that drives the 
behaviour, thus the information given by this test is inconclusive. It is a robust screening test 
but needs to be combined with other tests. The OF test consisted of a square plexiglas arena 
(approx. 35 x 35 cm). Each mouse was released in one corner, and could thereafter freely 
explore the environment for 30 min. Horizontal and vertical activities were detected by infra-
red beams and photoreceptor cells. 
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3.2.2.4 Passive avoidance 
The PA test is a classical conditioning test in which the mice learn to associate the dark 
compartment, where they receive an aversive stimulus (for example electric foot shock), with 
an aversive experience. After the conditioning, the animal makes during the memory testing a 
choice to enter the dark compartment where it received the foot shock or stay in the lit 
chamber. The latency to enter the dark compartment is measured. The test is hippocampus-
dependent but other cortical areas have been shown to contribute to aversive contextual 
association (Baarendse et al., 2008). The short-term memory was tested 1.5 h and the long-
term memory 24 h after the mice received the shock.  
 
3.3 Biochemical and morphological analyses 
3.3.1 Patient samples  
CSF and serum samples (Paper IV) from SCI, MCI, and AD patients with or without allergy 
were obtained from the Memory Clinic at Karolinska University Hospital, Huddinge, 
Sweden. CSF is secreted by the choroid plexus of all four ventricles, flows along the 
ventricular system and subarachnoid space and plays a key role in volume transmission i.e. 
distributing substances present in CSF within the brain and clearing the brain metabolites 
(Agnati et al., 1995). This makes CSF valuable material for providing insights about the brain 
although the substances present in CSF might not exactly mirror the processes occurring 
inside the brain. Blood analysis is interesting for studying systemic changes and is less 
invasive compared to CSF. However, analysis of both CSF and blood may represent global 
changes, thus local changes may not be detected with CSF and blood analysis.    
To comment on the study population, approximately 1800 patients visited the Memory clinic 
at Karolinska University Hospital, Huddinge between years 2007 and 2012, and 
approximately 20% of these patients had allergy according to the medical records, which 
could be representative with regards to the incidence of allergy. However, the Memory clinic 
at Karolinska University Hospital is located at the South of Stockholm and may be biased in 
terms of socioeconomic and ethnic groups compared to other parts of Stockholm or Sweden. 
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chamber. The latency to enter the dark compartment is measured. The test is hippocampus-
dependent but other cortical areas have been shown to contribute to aversive contextual 
association (Baarendse et al., 2008). The short-term memory was tested 1.5 h and the long-
term memory 24 h after the mice received the shock.  
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These aspects cannot be overlooked when generalising data for a whole population. 
Furthermore, patients with allergies represented a rather heterogeneous group as allergic 
diseases included several types of allergies that were either self-reported or diagnosed by 
physician. The effects of different types of allergies on brain might not be the same and the 
reliability of self-reports for different conditions may vary. It is possible that allergies are 
under-reported at the memory clinic and therefore the presence of allergic patients in the 
groups without allergy cannot be excluded. We did not have information about the duration 
of allergies, which could lead to variation among subjects with allergy.      
 
3.3.2 Allergy confirmation in bronchoalveolar lavage 
The aim of collecting BAL fluid from mice was mainly to confirm allergy (Paper I, III). 
The animals were sacrificed 24 h after the last antigen challenge. After collecting the brain 
tissue, the lungs were dissected out and the trachea was cannulated with a catheter. The 
lungs were carefully flushed twice with ice-cold PBS while the lobes were manually 
massaged to ensure even fillings of the lungs. The recovered BAL fluid was centrifuged 
and the cells were spinned onto glass slides, air-dried, fixed in ethanol, and stained with the 
May-Grünwald/Giemsa method. The number of eosinophils, macrophages, neutrophils and 
lymphocytes were counted on the basis of morphology.  
 
3.3.3 Antibody-based techniques 
3.3.3.1 Western blotting 
Western blot is an antibody-based semi-quantitative method where proteins are separated 
with regard to their molecular mass in an electric field and subsequently visualized as bands 
with the aid of target-specific antibodies. Information about the molecular weight (MW) of 
the band on the blot could serve as a checkpoint to confirm that antibody has bound the 
correct protein. However, proteins are subjected to post-translational modifications, which 
influence their MWs and therefore the MW observed on the blot could be sometimes 
different than the theoretical MW. Western blots were performed on brain homogenates from 
mice (Paper I, II, III). Bound antibodies were detected with enhanced chemiluminescence 
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(ECL) using charged-couple device camera and the optical density of bands was measured 
using Multi Gauge (version 3) software.  
 
3.3.3.2 Immunohistochemistry  
Immunohistochemistry is a valuable technique for studying protein expression. It is a semi-
quantitative technique as western blot but with the advantage of providing information about 
the localization of the protein of interest in the tissue or cell being studied. For IgG, IgE, 
CD138 staining (Paper I) and CD64 staining (Paper III), the sections were incubated for 30 
min with 5% normal serum and subsequently incubated with primary antibodies at 4 °C 
overnight. For visualization with fluorescence (CD138) (Paper I), the sections were 
incubated with flourophore-conjugated secondary antibody for 1 h, at room temperature 
(RT). For visualization with diaminobenzidine (DAB) (Paper I, III) the sections, after 
incubating for 1 h at RT with appropriate biotinylated-secondary antibodies, were exposed to 
streptavidin-horse radish peroxidase complex for 30 min at RT. The immunoreactivity was 
visualized by incubation with DAB in the presence of H2O2 for 3 min. The slides were 
analysed under light microscopy (Nikon Eclipse E800) and photographed. For CD64 
staining, antigen retrieval was performed, which due to protein denaturation may result in 
epitope unmasking.    
  
3.3.3.3 Cytokine assays 
The levels of pro- and anti-inflammatory cytokines in mouse homogenates (Paper I, Paper 
III) and human CSF and serum (Paper IV) were analysed with multiplex assays developed 
by Meso Scale Discovery (MSD) technology, which is a modified version of enzyme-linked 
immunosorbent assay (ELISA). The MSD assay relies on the binding of the antigen to a 
capture antibody followed by detection with a tagged secondary as in traditional ELISA but 
uses electric signal in addition to ECL signal to minimize background signal. The main 
advantage of MSD technique is the simultaneous measurement of multiple analytes and a 
volume requirement of 25-50 μL per sample. Another advantage is the wide range of the 
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standard curve compared to traditional ELISAs. The disadvantage of this method with regard 
to cytokine measurement, at least in our experience, was the reduced sensitivity compared to 
traditional ELISAs.  
 
3.3.3.4 Immunoglobulin assay 
The levels of IgM, IgA, IgG subclasses and the total IgG levels were analysed in the CSF 
and serum (Paper IV) using a 7-plex human isotyping panel and a single-plex (for total 
IgG) developed by MSD.   
 
3.3.4 DNA-based techniques  
3.3.4.1 Microarrays 
We performed microarrays (Paper II) to obtain an overview of genes/pathways that were 
changed by allergy in the brain. Microarrays were performed in the hippocampus and 
frontal cortex using Affymetrix whole-transcript expression analysis in association with 
Bioinformatics and Expression Analysis Core Facility (BEA), Karolinska Institute. Briefly, 
the mRNA was extracted, reverse-transcribed to single stranded cDNA and hybridized to 
the probes on microarray chip. The fluorescence of the bound cDNA to the corresponding 
probes was measured. The array plate contains more than 770,000 oligonucleotide probes 
(25-mere) that cross-examine more than 28,000 annotated genes.  
Parallel analysis of all genes expressed in a tissue makes microarrays a powerful tool for 
studying the complex networks of biological processes. Mircroarrays could be useful in 
multiple medical applications e.g. understanding the molecular characteristics of diseases, 
identification of new therapeutic targets and classification of sub-groups in a disease to 
identify individualized treatments (Tarca et al., 2006). Microarrays generate large datasets 
and a plethora of factors contribute to the observed differences in gene expression between 
control and treated samples including: 
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a) Technical factors (related to sample and sample preparations) 
b) Systemic factors (difference between arrays, reagents, instrumentation) 
c) Biological factors (true variation) 
In order to extract differential expression due to biological variation and to interpret the 
results, the microarray dataset is processed mainly in the following steps: (i) quality control 
to provide information on homogeneity (technical variation) of sample groups, (ii) 
preprocessing such as normalization to account for systemic variation and to enhance or 
extracts the meaningful characteristics of the dataset, (iii) detection of differentially 
expressed genes (DEGs) i.e. identify genes that are changed due to biological variation, and 
(iv) functional profiling of DEGs i.e. to extract biological knowledge (e.g. pathways, 
biological processes) using Gene Ontology approaches (Cordero et al., 2007). In contrast to 
univariate measures, which are limited to studying single molecule at a time, the 
multivariate measures in microarrays allow to study whether multiple genes in a 
pathway/category are over-/under-represented among the DEGs, thus enhancing the 
reliability of the result (Blalock et al., 2005). 
Despite holding great promises, microarrays bring a number of problems. It is difficult to 
determine whether the changes in gene expression are functionally relevant, compensatory, 
or secondary to the process under the study (Blalock et al., 2005). Due to high frequency of 
false positives and false negatives in large datasets, validation of microarray findings with 
reference methods such as polymerase chain reaction (PCR) is recommended (Rajeevan et 
al., 2001; Wang et al., 2006), although a robust correlation between Affymetrix arrays and 
PCR was reported (Lee et al., 2008). In the brain, the changes in expression are relatively 
moderate and small changes may have biological significance (Soverchia et al., 2005), thus 
making it difficult to distinguish true DEGs from noise. Therefore the dataset is more prone 
to include high rate of false positives and thus validation with PCR might be exclusively 
necessary.  
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3.3.4.2 Polymerase chain reaction  
PCR is an alternative approach for studying gene expression that, as microarrays, relies on 
conversion of mRNA to cDNA (for review see (Kubista et al., 2006)). In contrast to 
microarrays, PCR allows for studying only one gene at time (per reaction well). PCR is 
more sensitive and, in our experience, more specific than microarrays. For example, to PCR 
reaction one could add target specific Taqman probes, which are short DNA sequences that 
span over exon regions to ensure that the amplified product in PCR reaction comes from 
the gene of interest. PCR was used (Paper II) as an alternative approach to validate the 
findings from microarrays. For quantification, the comparative cycle threshold (Ct) method 
with the arithmetic formula 2ΔΔCt was used, which is only valid under the assumption that 
the amplification efficiency of the gene of interest and the reference gene is approximately 
equal. The reference gene – β-actin in our case – is used as an internal control for the 
amount of mRNA input in the PCR reaction.  
One of the limitations regarding gene expression analysis (DNA-based methods) is that it 
does not take into account the post-transcriptional events. Protein is the functional unit of 
the cell and therefore information at mRNA level is not sufficient to describe the state of 
the cell.    
 
3.4 Statistics 
3.4.1 Univariate statistics 
Statistical analysis was performed with SPSS software (IBM, Corporation, NY, USA) and 
the R software package (GNU General Public Licence) was used for graphic presentations.  
Normally distributed data was analysed with Student’s t-test or one-way ANOVA followed 
by post hoc Bonferroni test or two-way ANOVA (Paper I, II, III), whereas non-normally 
distributed data was analysed with Mann-Whitney test (Paper I, II, III, IV). For all the 
studies, 95 % confidence interval and p-values < 0.05 was used.   
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3.4.2 Multivariate statistics 
Multivariate analysis (MVA) (Paper II) was performed with SIMCA P+ software package 
(UMETRICS AB, Umeå, Sweden). The data were preprocessed by unit variance (UV) 
scaling and mean-centering. UV scaling allows comparison of completely different variables, 
such as behavioural activity in OF and cytokine levels obtained by ELISA. UV scaling uses 
the inverse standard deviation as a scaling weight for each variable to scale variables with 
higher level of variance with those with a lower variance. Mean-centering improves the 
interpretability of the data, by subtracting the average for each analysed variable, thus 
repositioning the dataset around the origin. The resulting data were fed into principle 
component analysis (PCA), and subsequently into orthogonal projection to latent structure-
discriminant analysis (OPLS-DA). 
PCA is an unsupervised multivariate technique mainly used to obtain an overview of the data 
by representing the multivariate data as a low-dimensional plane, usually consisting of 2 to 5 
dimensions (Eriksson, 2006). The extracted information is projected in a set of new 
orthogonal variables called principle components (PCs). The direction that accounts for the 
largest variation in the datasets determines the direction of the first PC (PC1). The direction 
for PC2 is orthogonal to PC1, and accounts for the second largest variation. Subsequent PCs 
will describe the decreasing variability in a sequential manner, where each PC will be 
orthogonal to the direction of the previous PC. PCA gives an overview of the data by 
presenting the patterns of similarities in the observations (samples) and variables, as points in 
a score plot and a loading plot, respectively.  
OPLS-DA is a supervised multivariate regression and prediction method used to describe the 
association between a quantitative data matrix X (in our case DEGs), and qualitative values 
in a Y vector (in our case control and allergy) (Wiklund et al., 2008). OPLS-DA separates the 
variation observed in X into two components: (i) the variation containing information related 
to Y and presented in the first predictive component (t1) of the score plot (in our case the 
variation related to the allergy), and (ii) the variation not related to Y and presented in the 
second (orthogonal) component of the score plot (t2) (in our case the variation unrelated to 
allergy). Separation of data unrelated to Y into orthogonal component facilitates the 
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interpretation of data (Holmes et al., 2006). The variables that are important for the class 
separation are represented in the loading plot with their corresponding jack-knifed intervals. 
The y-axis in the loading plot represents covariance (Wiklund et al., 2008), and variables 
with high covariance (positive and negative) are more likely to have impact on class 
separation. 
The number of components in PCA and OPLS-DA depends on R2 (estimation of fit) and Q2 
(estimation of prediction) values. The calculation of the Q2 value was based on seven-fold 
cross validation (CV), in which 1/7th of the dataset (variables) was omitted randomly to 
create several parallel predictive models. The omitted data were then predicted by the 
respective model.  
Jack-knifing is an approach used for finding the precision of an estimate. In PCA and OPLS-
DA, jack-knifing uncertainty measures of scores and loadings are calculated from the set of 
multiple models generated from CV (Martens H et al., 2001). Confidence intervals that 
include zero have low reliability (Wiklund et al., 2008).   
 
3.5 Ethics 
The studies involving mice were approved by the Stockholm South Ethical Committee for 
animal experiments with the following ethical numbers: S200/07 (Paper I), S204/10 (Paper 
II), S158/12 (Paper III).  
The study involving human CSF and serum samples (Paper IV) was approved by the 
Southern regional ethics committee of Stockholm with the ethical number 2011/680-31/1.  
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4 RESULTS AND DISCUSSION 
4.1 Cell counts in the bronchoalveolar lavage  
The analysis of BAL fluid was performed in Balb/c, C57BL6 (Paper I), 3xTgAD, and Bg 
(B6129SF1) mice (Paper III) to validate the allergy model. The number of eosinophils in the 
BAL was significantly increased in all mice confirming the presence of allergy (Fig. 2A). An 
increased number of eosinophils, or their molecular products, such as major basic protein, 
eosinophil cationic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin, are 
found in allergic diseases, but most of the studies are performed in asthma (Wardlaw et al., 
2000). In patients with mild asthma, the BAL fluid showed eosinophilia with normal 
neutrophil counts (Wardlaw et al., 1988), whereas the presence of neutrophils in the BAL is 
associated with severe asthma. However, both neutrophils and eosinophils have been reported 
to occur in the BAL of patients with allergic asthma (Frangova et al., 1996). In our model of 
airway allergy we found increased levels of neutrophils in response to OVA in all the strains 
except for Balb/c mice (Fig. 2B). The increase in eosinophils in the BAL of Balb/c mice and 
of neutrophils and eosinophils in the BAL of C57B6 mice are in agreement with previous 
work (Whitehead et al., 2003), but neutrophilia has been reported also in the Balb/c mice 
(Gueders et al., 2009). Eosinophils have been shown to increase 24 h post challenge in the 
BAL in several strains of mice (Whitehead et al., 2003), and in the blood in asthmatic 
patients (Djukanovic et al., 1990). We found that the total number of cells, reflecting 
eosinophils, neutrophils, macrophages, and lymphocytes in the BAL was significantly 
increased with allergy in all strains of mice (Fig. 2C), in agreement with studies in mice 
(Drent et al., 1993; Whitehead et al., 2003), but not in asthmatic patients (Smith, 1992). 
However, in other types of human allergic diseases such as extrinsic allergic alveolitis 
(EAA), the total number of cells in the BAL was increased, but was dependent on the time 
elapsed after antigen exposure (Drent et al., 1993). Compared to control subjects, patients 
with EAA had higher counts of eosinophils, neutrophils, macrophages, and lymphocytes in 
the BAL 2 - 7 days after antigen exposure, whereas no differences were found before 24 h, 
and at 8 - 30 days or 1 - 12 months after antigen exposure (Drent et al., 1993).   
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Strain-related differences were found in the total number of cells in BAL in the absence of 
allergy (Fig. 2C). The basal levels of eosinophils in the BAL of Bg mice, in the absence of 
allergy, were significantly higher than the basal levels in Balb/c and C57B6 mice, indicating 
strain-related differences also regarding eosinophils (Fig. 2A). However, Tg animals had 
significantly lower eosinophil cell counts and a lower trend in the neutrophils than Bg mice 
(their background strain), indicating differences induced by the transgene or pathology. 
During dissection, one could identify allergic animals from the “texture” of the lungs in Bg 
animals but this distinction was not clear from the lungs of the transgenic animals 
(unpublished observations). It would be of interest to study the lungs of patients with AD 
with regard to morphology, the presence of immune cells, and their molecular derivatives, 
especially knowing that respiratory infections such as pneumonia are frequently encountered 
in AD patients.   
 
Fig. 2. Allergy-induced changes in immunocompetent cells in bronchoalveolar lavage (BAL) fluid 
from 3xTgAD and Wildtype mice. Allergy was induced in mice using ovalbumin (OVA) as allergen. 
Eosinophils (A), neutrophils (B), and total cells (C) (reflecting eosinophils, neutrophils, macrophages 
and lymphocytes) were counted based on their morphology. The boxplots indicate interquantile range 
(IQR), the upper whisker is 1.5 IQR + Q3, the lower whisker is 1.5 IQR - Q1, and the line in the 
middle shows the median. Con = control, OVA = allergic, Bc = Balb/c, C57 = C57BL6, Tg = 
3xTgAD, Bg = background strain for 3xTgAD. The circles are outliers. * P < 0.05, *** P < 0.001. # 
indicates significant difference between allergy and controls animals within the strain, + indicates 
significant difference between Tg-con and C57-con as well as Tg-con and Bc-con mice. 
Although we have confirmed the presence of allergy by performing analysis in the BAL, one 
of the limitation of our allergy model is that we have not performed the routine analysis to 
validate the allergy model i. e. to analyze the cytokine profile in the lungs, the presence of 
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IgE and IgG1 in the lungs, the inflammation in the lung sections, and the airway 
hyperresponsiveness.  
4.2 Immunoglobulins in allergy and Alzheimer disease 
4.2.1 Animal studies 
Allergy was associated with a consistent increase in the levels of IgG and IgE in the brain of 
all the strains of mice (Paper I, II, III). At basal conditions, IgG-like immunoreactivity has 
been reported in C57BL6 and Balb/c mice on microglia, and also on macrophages and 
epithelial cells in the choroid plexus (Hazama et al., 2005). We found an increased IgG 
staining not only around the cerebral blood vessels, but also widely distributed in the brain 
parenchyma (Paper I). The same distribution pattern of IgG was found in a mouse model of 
prion disease following systemic inflammation induced by LPS (Lunnon et al., 2011), 
indicating that an increase in the brain levels of IgG is not unique to allergy. Assuming that 
the Igs observed in the brain enter from the periphery, there are several possible routes and 
mechanisms suggested, such as: a) leakage at sites lacking BBB as in the CVOs; or b) Ig-
secreting cells infiltrating the brain (Hazama et al., 2005); c) a selective transporter at the 
BBB interface - the presence of a saturable transport system for IgG has been reported in the 
guinea pig (Zlokovic et al., 1990); d) neonatal FcR may play role in the transport of Ig across 
the BBB (Deane et al., 2005; Giragossian et al., 2013). To study whether Ig-secreting cells 
enter the brain, we stained the brain sections of mice with CD138, a marker for plasma cells, 
a major source of Igs (Kitamura et al., 1991). However, more recent studies have revealed 
neuronal Ig synthesis in both rat and human brain (Niu et al., 2011; Zhang et al., 2013a). The 
brain of allergic mice did not show any immunoreactivity for CD138, indicating that the Ig 
was not secreted locally by B-cells in the brain (Paper I). Infiltration of IgG-secreting plasma 
cells in the brain (Knopf et al., 1998), and formation of an IgG-OVA immune complex (IC) 
(Carare et al., 2013) in OVA-sensitized rodents only occurred when OVA was microinjected 
intracerebrally. In our studies, the formation of ICs in the brain is unlikely, as the traffic of 
big proteins such as OVA across the BBB presumably does not occur. It cannot be excluded 
that increased IgG levels in the brain of allergic mice may reflect a combination of both 
peripherally derived and locally synthesized IgG. It was recently shown that about 0.01% of 
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peripherally administered intravenous IgG (IVIG) in 3xTgAD mice reached the cerebral 
cortex, possibly by a saturable transporter (St-Amour et al., 2013). The functional relevance 
of increased Ig levels in the brain remains unknown. Zhang et al. showed that complement 
exposure (Zhang et al., 2013a), or administration of 6-hydroxydopamine (6-OHDA) 
increased the expression of IgG in primary neurons, and that primary neurons were dose-
dependently protected against 6-OHDA-induced injury after treatment with neuron-derived 
IgG (Zhang et al., 2013b). It is thus possible that IgG plays a role in immunomodulation in 
CNS.  
IgG is present in four subclasses in humans (IgG1 - IgG4) and mice (IgG1, IgG2a, IgG3b, 
IgG3), binds to FcγRs with various affinities, and regulates functions such as antibody-
mediated cell cytotoxicity, phagocytosis of ICs, and production of pro-inflammatory 
mediators (Sanchez-Mejorada & Rosales, 1998; Karsten & Kohl, 2012). In the CNS, 
expression of FcγRs has been found on microglia, neurons, astrocytes, and oligodendrocytes 
(Okun et al., 2010). As a follow-up on our finding of increase IgG levels in the brain, we 
analysed the levels of FcγRs in Bg and Tg mice (Paper III). In the absence of allergy, Tg 
mice expressed higher levels of FcγRI (CD64) compared to Bg mice. Allergy significantly 
increased the levels of FcγRI both in Bg and Tg animals and the difference was more 
pronounced in the dentate gyrus than the cortex or other hippocampal areas. In contrast to 
other FcγRs, FcγRI binds monomeric IgG with high affinity (Karsten & Kohl, 2012), and is 
expressed on astrocytes and microglia (Zhang et al., 2013a). FcγRI expression was increased 
and NO production was decreased in microglia treated with complement in the presence of 
IgG (Zhang et al., 2013a), suggesting a protective role for IgG in the brain. Passive 
immunization against Aβ in Tg2576 mice was followed by an initial increase in FcγRII and 
III in the brain, and enhanced phagocytosis of Aβ (Wilcock et al., 2004). However, the levels 
of FcγRs returned 3 months after immunization to the level in non-immunized mice. 
Similarly, post-mortem quantitative analysis performed seven years after immunization with 
Aβ1−42 revealed significantly lower levels of CD64 and CD32 in immunized AD patients than 
in controls (Zotova et al., 2013). Thus, the function of FcRs seems to be context-dependent 
similarly to other mediators of inflammation.   
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4.2.2 Human studies 
Allergy influences the levels of Igs in human. Serum levels of IgE were increased in patients 
with atopic diseases (Berg & Johansson, 1969) with a parallel increase in serum IgG to the 
same allergen (Chapman et al., 1983), in agreement with our data in mice. Other classes of 
allergen specific Igs, such as IgM and IgG subclasses (IgG1 - 4), are produced in the serum 
of patients with allergy (Niederberger et al., 2002), although the levels of IgG subclasses vary 
in asthmatic individuals (Loftus et al., 1988). To study the influence of allergy on Igs in AD, 
we analysed the levels of IgM, IgA, total IgG, and its subclasses (IgG1 - 4), in the CSF and 
serum of patients with AD, MCI or SCI, with or without allergy. In contrast to the mice, there 
was no increase in the total levels of IgG due to allergy in any of the patient groups (Paper 
IV), although the occurrence of “allergen-specific” IgG in patients with allergy cannot be 
excluded. Previous studies in patients with allergy showed increased levels of IgE in serum 
during antigen exposure (Henderson et al., 1975), and decreased levels after antigen 
avoidance (Sensi et al., 1994). This indicates that the levels of Igs in allergic patients are 
dependent on antigen exposures. In the patient material that we analysed, data were not 
available for variables such as antigen exposure before sampling of blood or CSF. 
Furthermore, the allergic groups consisted of patients with different types of allergies, which 
may influence the results and conclusions. Analysis of the IgE levels in patients allergic to 
dust mite antigen during the avoidance period showed that changes in mucosal IgE levels, 
which represent the local area, were more rapid than changes in serum levels (Sensi et al., 
1994). Therefore, blood and CSF analysis may be limiting in reflecting the local changes. We 
found a correlation between CSF and serum for IgG and IgA classes when the data from all 
patients were pooled, whereas no correlation was found for IgM, indicating possible local 
changes.    
In mice, IL-4 drives the polarization of T-cells to Th-2 cells, and the predominant IgG 
subtype is IgG1, whereas the Th-1 response is driven by IFNγ and is associated with IgG2a 
(Tabira, 2010). In humans, this distinction is not clear. The majority of studies on the levels 
of Igs in asthmatics were performed in children or in young adults. Since the levels of Igs 
change with age (Ritchie et al., 1998), the results may vary in very young vs old ages. To 
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study the influence of allergy on Ig classes in AD, we analysed the levels of IgM, IgA, and 
the IgG subclasses, IgG1-IgG4, in CSF and serum of patients with AD, MCI, and SCI with or 
without allergy (Paper IV). In cases without allergy, IgG1 to total IgG ratio was higher in 
AD compared to SCI or MCI. Allergy was associated with lower levels of IgG1 to total IgG 
ratio and IgA in the CSF of patients with AD compared to those without AD, whereas IgM 
levels in serum were higher in MCI patients with allergy compared to those with allergy. The 
levels of IgA in serum increase with age, whereas those of IgM decrease with age (Ritchie et 
al., 1998). Aging has been shown to increase the levels of IgG1, IgG2, and IgG3 (Paganelli et 
al., 1992; Listi et al., 2006). It seems that Ig responses were influenced by the presence of 
allergy in the patients in our material.  
 
 
 
 
 
 
Fig. 3. Allergy-induced changes in cytokines in different mouse strains. Allergy was induced in mice 
using ovalbumin (OVA) as allergen. The levels of interferon (IFN)-γ (A), and interleukin (IL)-1β (B) 
were analysed in the hippocampus by using multiplex cytokine kit developed by Mesoscale. The 
boxplots indicate interquantile range (IQR), the upper whisker is 1.5 IQR + Q3, the lower whisker is 
1.5 IQR - Q1, and the line in the middle shows the median. The age of Tg and Bg mice was 
approximately 7 months and that of C57BL6 mice was approximately 4 months at the end of the 
study. Con = control, OVA = allergic, C57 = C57BL6, Tg = 3xTgAD, Bg = background strain for 
3xTgAD. The circles are outliers. * P < 0.05 
 
4.3 The effects of allergy on the brain 
Mild asthma in healthy elderly (≥ 55 years) was associated with increased decline in 
cognition (Caldera-Alvarado et al., 2013), and asthmatics had 1.8 years shorter survival time 
compared to non-asthmatics (Eriksson et al., 2008). In patients with mild to moderate asthma, 
13 out of 21 subjects had abnormalities in their brain MRI scans (Parker et al., 2011), 
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indicating that allergic inflammation such as asthma affects the brain. We investigated the 
effect of chronic OVA-induced airway allergy on brain in naïve mice (Paper I, III), with 
regard to cytokines and AD-related proteins (tau and APP). Allergy increased tau 
phosphorylation at Ser202/Thr205 (AT8) and Thr231/Ser235 (AT180 site) phosphorylation 
sites (Amniai et al., 2009) in Balb/c and C57BL6 mice (Paper I), but not in Bg mice (Paper 
III), which showed a high variation both within the control group and the allergic group, ,. 
With regard to cytokines, allergy decreased the levels of IFNγ (Fig. 3) in C57BL6 mice, 
whereas increased IL-1β in Bg mice (Fig. 3). Interpretation of change in one cytokine is 
difficult, and there was no effect of allergy on phosphorylation of p38 and c-Jun N-terminal 
kinase (JNK), which are involved in production of cytokines. At low concentrations, IFNγ 
plays a role in neurogenesis (Butovsky et al., 2006), and one could argue that reduction of 
IFNγ in the brain due to allergy may influence its physiological role in the brain. In a recent 
study, OVA-induced allergy was associated with reduced neurogenesis and reduced synapse 
density in the hippocampus (Guo et al., 2013). Additional changes induced by allergy include 
the appearance of swollen, vacuolated, and damaged mitochondria, and reduced levels of c-
fos and activity regulated cytoskeleton associated protein in the hippocampus (Guo et al., 
2013). Furthermore, the allergic mice showed impairment in Morris water maze (MWM) test, 
as indicated by impaired learning during the training sessions and poor memory during the 
probe trails (Guo et al., 2013). However, treatment with Budesonide attenuated mitochondrial 
damage and increased neurogenesis in the allergic mice, without influencing the synapse 
density, or learning and memory (Guo et al., 2013). With regard to inflammation in the brain, 
we did not observe any difference in microglial or astrocyte activation as analysed with 
ionizing calcium-binding adaptor molecule 1 (Iba-1) and glial fibrillary acidic protein 
(GFAP), respectively (Paper I, III). In contrast, Xia et al. found that OVA-induced allergy 
was associated with increased microglial activation as analysed by cd11b, increased levels of 
TNFα, IL-1β, and TGFβ, and decreased levels of IL-10, in the hippocampus (Xia et al., 
2014). A possible explanation to the discrepancy between the two studies may be the allergy 
induction protocol. Thus, our challenge model lasted 5 weeks, whereas Xia et al. used a 
challenge phase of 9 weeks and, probably even more important, included sessions with 
exposure to high concentration of OVA to induce aggravation (Xia et al., 2014). Considering 
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the studies mentioned above, allergy seems to have negative consequences on the brain. It is 
difficult to conclude whether allergic disease may have positive or negative effects on the 
brain in the context of neurodegenerative diseases. Since inflammation may have both 
positive and negative consequences, the inflammatory environment in the brain, the timing, 
and the duration, may all be important factors in determining whether the effect of allergy on 
the brain is beneficial or detrimental.    
By using microarrays, we further analysed the effects of allergy on gene expression in the 
brain. Allergy reduced the levels of IDE in hippocampus, frontal cortex and hypothalamus 
(Paper II). In addition, allergy was associated with reduction in the phosphorylation of 
insulin receptor (IR) (Paper II). These findings suggest that allergy has a negative effect on 
insulin signalling in the brain, which is involved in regulating peripheral fat and glucose 
metabolism (Koch et al., 2008). Furthermore, metabolic diseases such as DT2 and obesity are 
associated with deficits of insulin signalling in the brain (Farooqui et al., 2012). Asthma has 
been associated with obesity and DT2 (Meng et al., 2014), and our findings warrant further 
studies on the link between asthma and metabolic disorders. These findings are also 
interesting in the context of AD, since both obesity (Letra et al., 2014) and DT2 are risk 
factors for AD. Furthermore, IDE is involved in the cleavage of Aβ and its levels are reduced 
in AD brain (Hickman et al., 2008). Taken together, these studies suggest that the presence of 
allergy may have negative consequences in subjects with predisposition to AD.  
Several other interesting genes were found to be upregulated in the brain upon allergy (Paper 
II). Recently, it was shown that mice exposed to chronic but not acute stress (induced by 
stressors such as animal dander), increased the expression of hemoglobin genes in prefrontal 
cortex (Stankiewicz et al., 2014). We found increased transcripts of hemoglobin genes in 
frontal cortex in mice exposed to allergy (Paper II), indicating that allergic diseases may 
result in increased stress on the brain. Several other interesting genes were altered in the 
microarray study, but for the reasons described below, it is necessary to validate each gene 
with other methods before any interpretation of the data. The complex architecture and 
function of the brain poses some challenges on microarray analysis of brain tissue. Primarily, 
the changes in gene expression in the brain are relatively moderate and consequently, small 
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changes may play a biologically significant role, but may be difficult to discriminate from 
noise. Therefore, the arbitrary cut-off level (> 2 fold change) may not apply for the brain. 
This means that the results may also include noise. Secondly, the intrinsic heterogeneity in 
the cell populations in the brain may dilute a significant fold change in the gene of interest if 
it is differentially expressed only in a portion of the cells. Lastly, an up-regulation of the gene 
in one cell population could possibly be counterbalanced by down-regulation of the same 
gene in the neighbouring cell population, and may thus end up undetected (Soverchia et al., 
2005).      
 
4.4 The effects of allergy in Alzheimer disease 
4.4.1 Animal studies 
As mentioned in the Introduction, epidemiological studies have shown that allergic diseases 
increased the risk for developing AD, and possible shared pathogenic pathways may be 
related to the observed association between AD and allergies. One such example is 
polymorphism in the IL-4 gene, which has been associated with increased risk for asthma 
(Micheal et al., 2013), and was recently shown to increase the risk for AD in a Chinese 
population (Li et al., 2014). The transgenic animal model of AD, 3xTgAD, was used to study 
the effect of allergy on the brain in the presence of AD-like pathology. The levels of 
inflammatory proteins, cytokines, C1q component C (C1qC), and decay accelerating factor 
(DAF), were analysed in the brain of 3xTgAD mouse strain and compared to Bg controls 
(Paper III). Allergy seemed to have differential effects in the presence or absence of AD-like 
pathology. In 3xTgAD mice, which had higher levels of inflammatory cytokines and C1qC 
levels in the brain, allergy decreased the phosphorylation of p38, increased the levels of 
mature brain-derived neurotrophic factor (BDNF) and DAF, which is a regulator of the 
complement system. BDNF is an important protective factor against development of 
dementia including AD (Weinstein et al., 2014), and has been shown to modulate 
inflammation by decreasing the levels of inflammatory cytokines (Jiang et al., 2010), and the 
activation of p38 (Tong et al., 2012). However, BDNF was implicated in neuronal 
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hypersensitivity and dysfunction in the airways in asthma (Prakash & Martin, 2014). DAF is 
a membrane-bound complement inhibitor found on microglia, astrocytes, and to lesser extent 
on neurons (Kolev et al., 2009). In AD brain, complement inhibitors were slightly increased 
compared to the complement proteins that were found to be substantially increased (Kolev et 
al., 2009), thus rendering the brain vulnerable to complement damage. Our findings suggest 
that allergy induces beneficial responses in 3xTgAD mice. In Bg animals, allergy increased 
the hippocampal levels of IL-1β and of C1qC, without inducing changes in the complement 
inhibitor DAF. Furthermore, allergy decreased p-IR levels, and decreased the burrowing 
activity in Bg mice. Taken together, our results suggest that allergy induced beneficial 
responses in the presence of AD-like pathology, whereas the opposite was found in the brain 
in the absence of AD-like pathology.  
Behavioural characterization revealed that at the age of four months, the 3xTgAD mice 
performed poorly in finding a hidden platform, and entering the dark chamber after 24 h, in 
the MWM and PA tests, respectively, indicating long-term memory deficits (Billings et al., 
2005b). At the age of 6 months, their short-term memory as measured by finding the hidden 
platform 1.5 h after the last trial in MWM, and performance in open field, were further 
deteriorated (Billings et al., 2005b; Gimenez-Llort et al., 2007). Differences between 
3xTgAD mice and wildtype mice in OF and PA have been reported previously (Clinton et 
al., 2007; Gimenez-Llort et al., 2007; Espana et al., 2010). In our study, the behavioural tests 
PA, OF and EPM, did not reveal any differences, neither between genotypes nor due to 
allergy (Paper III). Allergy was induced at the age of 4 - 5 months in Bg and 3xTgAD mice, 
and the mice were sacrificed at 6 - 7 months. In a previous study, at 6 month time point, naïve 
3xTgAD mice showed increased transcripts of TNFα and monocyte chemoattractant protein-
1 in the entorhinal cortex, but not in the hippocampus (Janelsins et al., 2005). Our studies 
showed increased levels of IL-1β, IL-8, and IL-12 in the hippocampus of the 3xTgAD mice 
(Paper III), indicating increased inflammation in the brain. There seems to be high 
variability between different colonies of 3xTgAD mice raised in different laboratories, which 
represent one of the main disadvantages of 3xTgAD mice. One such example is the 
discrepancy of the results between the original publication (Oddo et al., 2003) and the study 
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of Mastrangelo et al. with regard to the development of AD-like pathology (Mastrangelo & 
Bowers, 2008).   
4.4.2 Human studies         
We extended our studies from a mouse model of AD to humans in order to investigate 
whether allergy affects the AD biomarkers tau and Aβ, and whether there was any relation 
between the presence of allergy and MMSE scores in AD, as well as in cases with MCI and 
SCI. Allergy was associated with reduced t-tau levels in the CSF of AD patients compared to 
those without AD (Paper IV). CSF levels of t-tau and p-tau reflect neurodegeneration 
(Alzheimer's, 2013), and p-tau levels may have more specificity for AD (McKhann et al., 
2011). Despite lower t-tau levels in AD patients with allergy, the MMSE scores were not 
different between the groups. MMSE is not sensitive enough to detect differences between 
AD groups, but useful in detecting cognitive disturbance (Harvan & Cotter, 2006). With 
regard to MCI cases, the MMSE scores were higher in the presence of allergy than in cases 
without allergy, and there were no differences in t-tau or p-tau levels (Paper IV). One could 
argue that changes observed in allergic patients may be due to the anti-inflammatory 
treatment, and not to allergy. It was described that AD patients treated with corticosteroids, 
but not with NSAIDs, had reduced numbers of amyloid plaques and NFTs in the cortex 
(Beeri et al., 2012). In addition, the severity of dementia was higher in patients without anti-
inflammatory treatment compared to those receiving NSAIDs or glucocorticoids (Beeri et al., 
2012). However, in the study of Beeri et al., the majority of patients received glucocorticoids 
as treatment for allergic diseases, thus it is difficult to conclude if the protective effect was 
mediated by the treatment itself, the presence of allergic disease, or the combination of 
treatment and allergy. In Tg2576 mice, dexamethasone treatment for 28 days decreased tau 
phosphorylation without changing t-tau levels, but impaired behaviour in fear-conditioning 
paradigms (Joshi et al., 2012). In our study, we cannot exclude the potential bias due to anti-
inflammatory treatment in the allergic group although nearly comparable cases without 
allergy received glucocorticoid treatment. However, this evokes another important issue i.e. 
“how much controls are the controls?” The effects of anti-inflammatory treatments (NSAIDs 
and steroids) were analysed in relation to MMSE and CSF biomarkers (p-tau, t-tau and Aβ) 
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in the entire dataset, and also in SCI, MCI, and AD groups separately. The MMSE scores 
were significantly higher in allergic AD patients who received steroid treatment compared to 
those without steroid treatment. There were no effects of any anti-inflammatory treatment on 
the levels of CSF biomarkers. In a recent study, it was shown that the asthma drug disodium 
chromoglycate reduced the brain levels of Aβ in a mouse model for AD by inhibiting Aβ 
aggregation and inducing microglial clearance (Hori et al., 2014). Thus, the intake of 
different drugs in humans is challenging for the study design, especially if the study involves 
elderly people with many comorbidities.      
Analysis of cytokine levels in CSF samples revealed no differences between SCI, MCI, and 
AD cases with or without allergy. However, in patients without allergy, the serum IFNγ 
levels were higher in MCI than in AD. Also, MCI patients without allergy had higher IFNγ 
levels than MCI cases with allergy (Paper IV). The effect of change in one cytokine is not 
immediately obvious, and many immune cells in periphery produce IFNγ. Studies in mice 
have shown both detrimental and beneficial role of IFNγ in the context of AD. Induction of 
IFNγ expression at very young age in mouse models of AD was associated with a decrease in 
AD-like pathology (Chakrabarty et al., 2010a) and an increase in neurogenesis (Baron et al., 
2008; Mastrangelo et al., 2009). In contrast, adoptive transfer of IFNγ expressing Th-1 cells 
at the age of 8 - 9 months (prior to plaque development) exacerbated AD-like pathology and 
impaired performance in the MWM in Tg2576 mice. These effects were reversed with IFNγ 
neutralizing antibodies (Browne et al., 2013). With this background, it may be considered 
that reduced IFNγ levels in the serum of MCI patients with allergy could be beneficial. 
However, there was no correlation between serum IFNγ levels and MMSE scores in MCI 
patients with allergy. However, the interpretation of cytokine data is even more complicated 
considering that cytokine expression is a regulated process and thus prone to variation 
depending on time and physiological environment, even if we disregard variations due to 
technical reasons, or due to which body fluid is analysed. According to a recent meta-
analysis, the data on several cytokines have given inconclusive results. Thus, in the case of 
TNFα levels in plasma and serum, up-regulation, down-regulation, or no change, has been 
reported when comparing AD patients and age-matched controls (Brosseron et al., 2014). It 
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is conceivable that there are subgroups (or endotypes as described for asthmatics) of AD 
patients that have distinct cytokine profiles, which may explain the discrepancies in the 
results. In support of this view, Sudduth et al. found two populations within early AD 
patients: one with increased expression of pro-inflammatory markers (M1 type), and the other 
with increased levels of “anti-inflammatory markers” (M2 type) (Sudduth et al., 2013). 
Interestingly, AD patients in M2 group had higher prevalence of vascular risk factors 
(Sudduth et al., 2013). In the light of these findings, the previous reports on increased risk of 
cardiovascular disease in association with allergy (Mueller et al., 2013; Park et al., 2013), and 
our findings on deficits in insulin signalling in the brain induced by allergy, it is tempting to 
speculate that allergies (especially allergic diseases predominated by Th-2 responses) may be 
more prevalent within an AD subtype with “anti-inflammatory” profile. 
To summarize the data from patients, we found beneficial responses of allergy in AD patients 
in terms of a reduction in t-tau levels in CSF of patients with AD, and decreased levels of IgA 
and IgG1 ratio. In MCI, allergy was associated with an increase in MMSE scores, and 
reduced levels of IFNγ in the serum.    
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5 CONCLUDING REMARKS  
The aim of this thesis was to study the effects of allergy on the brain with focus on AD. In the 
first two studies, the effects of chronic airway allergy on the brain were investigated in the 
absence of AD-like pathology in mice. Subsequently, a mouse model for AD was used to 
study the effect of allergy on the brain in the presence of AD-like pathology. From these 
studies, we found that allergy induced presumably beneficial responses in the presence of 
AD-like pathology, whereas opposite responses were observed in the absence of AD-like 
pathology.  
In studies on human samples, the results pointed towards possible beneficial effects of allergy 
on AD pathology, as seen by biomarkers (tau in CSF), cognition test (MMSE), and 
inflammatory markers in CSF and serum.  
The key findings of this thesis could be summarized as follows:  
• Allergy increased the levels of IgG and IgE in the brain. The increase in Ig was 
localized to blood vessels and in brain parenchyma.  
• Allergy increased tau phosphorylation in the brain in the absence of AD-like 
pathology.  
• Allergy induced deficits in insulin signalling in terms of reduced IDE levels and 
reduced phosphorylation of IR in the brain in the absence of AD-like pathology.  
• Allergy increased the brain levels of mature BDNF, and of DAF, and decreased 
phosphorylation of p38, in the presence of AD-like pathology.  
• Allergy impaired burrowing activity in mice in the absence of AD-like pathology.  
• MCI patients with allergy had higher MMSE scores, higher serum IgM levels and 
lower serum IFNγ levels than those without allergy.   
• AD patients with allergy had lower levels of total tau in CSF, lower levels of IgA and 
of IgG1 ratio in CSF.  
To conclude - inflammation is a combination of extremely complex processes, which have 
the potential to become detrimental or beneficial for the host, depending on the type, timing, 
localization, and intensity of inflammatory response. The nature of the inflammation also 
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depends on the environment within the host. Therefore, the interpretation that allergy may 
have a beneficial role in AD may not be obvious, and further studies with better 
characterization of patients are necessary to investigate the role of allergy in relation to AD.   
  
6 FUTURE RESEARCH DIRECTIONS 
Epidemiological findings of an association between allergic diseases and an increased risk to 
developing AD suggest an interaction between the two diseases. Interestingly, the fact that 
both allergic diseases (Zhao et al., 2014) and AD (Driver, 2014) are inversely associated with 
cancers may strengthen the suggested positive association between allergy and AD. Study 
designs with “bridging approaches” as in this thesis requires collaboration between memory 
clinic and allergy clinic in order to obtain a better characterization of patients both with 
regards to allergies and AD. Therefore, the data derived from such studies will provide more 
precise information about the relationship between the two diseases.   
 Allergic diseases are often manifested at a young age, whereas AD has a late onset. Early 
immune stimulation in mice was shown to induce AD-like pathology in the brain later in life 
(Krstic et al., 2012). Therefore, it will be interesting to investigate the relationship between 
childhood allergies and the development of dementia later in life.  
Allergic asthma has several phenotypes and it will be of interest to analyse the association of 
different asthma phenotypes with AD, both in an epidemiological setting, and in a 
prospective study design. In addition, proper functioning of the brain relies on sufficient 
oxygen supply and dysfunctional lungs may induce hypoxic conditions both peripherally and 
centrally. Therefore, it would also be of interest to correlate the severity of asthma with AD-
pathology in the brain.  
FAD accounts for only about 5% of the total AD cases, but represents a very interesting study 
population considering the fact that all individuals with FAD mutations will develop AD.  It 
would thus be intriguing to investigate the association between allergy and AD in FAD cases 
at different ages. There are several questions that could be addressed. How prevalent are 
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at different ages. There are several questions that could be addressed. How prevalent are 
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allergic diseases in children with a FAD mutation? How does allergy affect the onset of AD 
in FAD cases? Th-2 stimulation in mouse models of AD in association with vaccinations was 
protective (Tabira, 2010), and our findings suggest a protective role of allergy. In FAD cases, 
Aβ plays an important role in the pathology, as in mouse models for AD - would allergic 
diseases with a predominant Th-2 phenotype, such as allergic asthma, be protective in FAD?  
Allergy is positively associated with metabolic and vascular diseases, which are risk factors 
for AD. Thus, it will be of interest to investigate the prevalence of allergy in AD cases that 
show more vascular pathology. Such studies will allow identification of more homogenous 
subgroups within the AD population, and may lead to development of personalized therapies.  
In the study of Rusanen et al., late-life asthma was associated with a decreased risk for AD, 
whereas, asthma was associated with an increased risk (Rusanen et al., 2013). Studies in mice 
can be used to address mechanistic questions regarding these associations. Since both timing 
and duration of inflammation influence AD-pathology differentially, the mouse models for 
AD offer appropriate tools to study the aspect of time. Studies on mice would allow 
investigation of how AD-like pathology evolves by analysing the brain at different old ages, 
after induction of allergy in early ages. Since timing of inflammation could affect the 
beneficial and detrimental role of inflammation, it would also be of interest to induce allergy 
in old mice and analyse the effects on the brain, both in wildtype and in mouse models for 
AD.   
Final reflection 
In conclusion, I will just add that in life there are more questions than answers, we have to 
endeavor ourselves in seeking answers, which however will generate more questions. In the 
case of studies on association between allergy and AD, in addition to the proposed designs 
above, approaches like microarrays or proteomics in mouse models of AD and patient 
material will provide a better insight into the different pathways that could be altered due to 
allergy. 
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